PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

23rd Congress of EHA

14-17 June 2018 Stockholm

N. Poster

Poster title

Applicant name

Status


156-PF	A NEW HUMANIZED MONOCLONAL ANTIBODY AGAINST A SPECIFIC GLYCOSYLATED EPITOPE OF CD43 ANTIGEN FOR THE THERAPEUTIC TARGETING OF ACUTE LYMPHOBLASTIC LEUKEMIA T (T-ALL)	Cirino Botta	Received

157-PF	CDK8 DEGRADATION - PREPARING THE GROUND FOR MTOR INHIBITION IN BCR/ABL+ ALL	Ingeborg Menzl	Received

158-PF	CD123 X CD3 BISPECIFIC DART® MOLECULE EFFICIENTLY ACTIVATES T CELLS TO KILL PRIMARY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA CELLS	Dragana Slavkovic Lukic	Received

159-PF	POTENT PRECLINICAL ACTIVITIES OF CD9 ANTIBODIES AGAINST HIGH-RISK PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Kam Tong Leung	Received

160-PF	PRECLINICAL DEMONSTRATION OF INTRACELLULAR ACTIVITY OF ASPARAGINASE ENCAPSULATED IN RED BLOOD CELLS BOTH IN THE ABSENCE AND IN THE PRESENCE OF NEUTRALIZING ANTI-ASPARAGINASE ANTIBODIES	Karine Aguera	Received

161-PF	CIRCULAR RNAOME VARIATION IN NORMAL HEMATOPOIESIS AND MLL REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA	Stefania Bortoluzzi	Received

163-PF	INTEGRATED GENETIC AND EPIGENETIC ANALYSIS ELUCIDATED EXPRESSION AND METHYLATION PROFILES OF ACUTE LYMPHOBLASTIC LEUKEMIA IN DOWN SYNDROME	Yasuo Kubota	Received

167-PF	TARGETING WNT10B*R-MEDIATED AUTOCRINE WNT SIGNALING ACTIVATION IN ACUTE LYMPHOBLASTIC LEUKEMIA	Adriana Cassaro	Received

168-PF	MIR-451 IS A NEW BIOMARKER THAT IDENTIFIES ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WHO MAY BENEFIT FROM TREATMENT WITH NAMPT INHIBITORS	Keren Shichrur	Received

171-PF	S100A16 INHIBITED PROLIFERATION AND PROMOTED APOPTOSIS THROUGH REGULATION OF ERK PATHWAY IN B CELL ALL	Jing Zhang	Received

172-PF	MELATONIN INHIBITS MLL-REARRANGED LEUKEMIA VIA RBFOX3/HTERT AND NF-?B/COX-2 SIGNALING PATHWAYS	Yan-Lai Tang	Received

173-PF	INVESTIGATING THE SYNERGISM BETWEEN CHK1 AND WEE1 PROTEINS INHIBITION IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA	Andrea Ghelli Luserna Di Rora	Received

185-PF	BLINATUMOMAB AND TYROSINE KINASE INHIBITORS COMBINATION IN RELAPSED/REFRACTORY ACUTE LYMPHOBALTIC LEUKEMIA: PRIMARY RESULTS AND LATE EVENTS	Andrey Sokolov	Received

188-PF	LONG TERM OUTCOME OF 138 ALO TRANSPLANTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA ON A SINGLE TRANSPLANT CENTER IN SPAIN	Irati Ormazabal Velez	Received

189-PF	EPIGENOMIC ANALYSIS REVEALS STEM CELL-LIKE RELAPSE SIGNATURE IN PEDIATRIC ACUTE MYELOID LEUKEMIA	Caroline Wiggers	Received

191-PF	NOVEL MUTATIONS AND TRANSLOCATIONS INVOLVING NUCLEOPHOSMIN (NPM1) GENE IN ACUTE MYELOID LEUKEMIA (AML) AND LEADING TO ABERRANT CYTOPLASMIC NPM1	Maria Paola Martelli	Received

192-PF	THE LSC17 SCORE ALLOWS RISK STRATIFICATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA	Nicolas Duployez	Received

193-PF	MUTATION PROFILE AND BENEFIT OF GEMTUZUMAB OZOGAMICIN IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED IN THE ALFA-0701 TRIAL	Elise Fournier	Received

194-PF	MOLECULAR PATHOGENESIS OF DISEASE PROGRESSION IN MLL-REARRANGED AML	Hideki Makishima	Received

196-PF	THERAPEUTIC TARGETING OF THE LEUKAEMIC FUSION GENE RUNX1/ETO VIA RNAI	Hasan Issa	Received

198-PF	LONGITUDINAL GENOMIC AND TRANSCRIPTOMIC TRACKING OF CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA	Taehyung Kim	Received

200-PF	FUNCTIONAL PROTEOMICS ANALYSIS OF AML-RELATED NUP98-FUSION PROTEIN INTERACTOMES	Stefan Terlecki-Zaniewicz	Received

201-PF	THE PNT DOMAIN OF ERG REGULATES HEMATOPOIETIC STEMNESS, YET IS NOT ESSENTIAL FOR ERG INDUCED ACUTE MYELOID LEUKEMIA	Eitan Kugler	Received

202-PF	FUNCTIONAL ANALYSIS OF EPIGENETIC AND TRANSCRIPTOMIC EFFECTS OF CEBPA MUTATIONS IN ACUTE MYELOID LEUKEMIA	Elizabeth Heyes	Received

203-PF	DETECTION OF MEASURABLE RESIDUAL DISEASE (MRD) BY ULTRADEEP NEXT GENERATION SEQUENCING (NGS) IS HIGHLY PREDICTIVE OF OUTCOME IN NPM1 MUTATED ACUTE MYELOID LEUKEMIA (AML)	Nikhil Patkar	Received

205-PF	NOVEL DEEP TARGETED SEQUENCING METHOD FOR MINIMAL RESIDUAL DISEASE MONITORING IN ACUTE MYELOID? LEUKEMIA	Esther Onecha De La Fuente	Received

208-PF	PROFILING AND FUNCTIONAL ANALYSIS OF CIRCULAR RNAS IN ACUTE PROMYELOCYTIC LEUKEMIA AND THEIR DYNAMIC REGULATION DURING ALL-TRANS RETINOIC ACID TREATMENT	Shufen Li	Received

210-PF	A POSSIBLE FIRST TIER SCREENING TEST TO DETECT TRANSLOCATIONS IN LEUKEMIAS USING TARGETED LOCUS AMPLIFICATION	Eva Van Den Berg	Received

211-PF	FUNCTIONAL EVALUATION AND MECHANISM RESEARCH OF KEL AND CIRC-KEL IN AEL	Hui Jin	Received

212-PF	A NOVEL BET-BROMODOMAIN INHIBITOR, ODM-207, AS A POTENTIAL THERAPY FOR ACUTE MYELOID LEUKEMIA	Juho Jalmari Miettinen	Received

215-PF	SOMATIC MUTATIONS IN RELAPSED ACUTE MYELOID LEUKEMIA	Samuli Eldfors	Received

216-PF	EXPRESSION OF PIWI-INTERACTING RNAS (PIRNAS) AND ITS PROGNOSTIC IMPLICATION IN ACUTE MYELOID LEUKEMIA (AML): A 3-PIRNA SCORING SYSTEM PREDICTS PROGNOSIS IN AML PATIENTS	Ta-Chuan Yu	Received

217-PF	BASOPHIL-LINEAGE COMMITMENT IN ACUTE PROMYELOCYTIC LEUKEMIA PREDICTS FOR SEVERE BLEEDING AFTER STARTING THERAPY	Sergio Matarraz	Received

220-PF	A GROUP OF EMA-APPROVED IMMUNOMODULATORS TARGETS AML STEM CELLS BY SABOTAGING THE CELLULAR RECYCLING MACHINERY	Josep Maria Cornet Masana	Received

221-PF	EXPLORING ALTERNATIVE TREATMENTS TO IMPROVE OUTCOME FOR PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA	Katrina Lappin	Received

222-PF	INTEGRATIVE ANALYSIS OF GENOMIC DATA REPOSITIONS THE USE OF 5´-AZACYTIDINE AND DECITABINE IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATMENT	maria rosaria sapienza	Received

224-PF	5-AZACYTIDINE ENHANCES THE ANTI-LEUKEMIC ACTIVITIY OF IDH1 INHIBITOR BAY 1436032 IN VIVO IN IDH1 MUTANT ACUTE MYELOID LEUKEMIA	Anuhar Chaturvedi	Received

225-PF	COMBINATORIAL CSF3R AND RUNX1 MUTATIONS INVOLVED IN THE LEUKEMIC PROGRESSION OF SEVERE CONGENITAL NEUTROPENIA CONFER A G-CSF-DEPENDENT PREMALIGNANT STATE IN MICE TERMINATING IN G-CSF INDEPENDENT AML	Patricia Olofsen	Received

226-PF	IDENTIFYING NEW DISEASE GENES IN FAMILIAL MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA	Ana Rio-Machin	Received

227-PF	ADDITION OF CRENOLANIB TO STANDARD INDUCTION AND CONSOLIDATION THERAPIES IMPROVED LONG-TERM OUTCOMES IN NEWLY DIAGNOSED FLT3-MUTANT AML PATIENTS = 60 YEARS OLD	Roland B. Walter	Received

228-PF	COMBINATION OF IDARUBICIN, CYTARABINE AND CLADRIBINE AS INDUCTION REGIMEN FOR UNTREATED ADULT AML AGED 60 OR YOUNGER: A PHASE III RANDOMIZED CLINICAL TRIAL	Jia Chen	Received

229-PF	REASSESSING THE PROGNOSTIC SIGNIFICANCE OF RECURRING CHROMOSOMAL ABNORMALITIES AND FLT3-ITD IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: AN ALWP/EBMT ANALYSIS	Jonathan Canaani	Received

233-PF	IMPACT OF CONCOMITANT EXPRESSION OF CD200 AND BCL2 ON OUTCOME OF ACUTE MYELOID LEUKEMIA	Mario Tiribelli	Received

235-PF	CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND T(8;16)(P11;P13): RESULTS FROM AN INTERNATIONAL COLLABORATION	Sabine Kayser	Received

238-PF	SAFETY AND PHARMACOKINETICS OF A NOVEL ORAL CAPSULE FORMULATION OF ARSENIC TRIOXIDE, ORH-2014, IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS	Farhad Ravandi-Kashani	Received

242-PF	RISK FACTORS OF EARLY DEATH FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA UNDER THE TREATMENT OF ATRA, ATO WITH OR WITHOUT CHEMOTHERAPY	Li Chen	Received

244-PF	OUTCOME OF A REAL-LIFE POPULATION OF ACUTE PROMYELOCYTIC LEUKEMIA TREATED ACCORDING TO PETHEMA LPA 2005 PROTOCOL: THE POLISH ADULT LEUKEMIA GROUP (PALG) EXPERIENCE.	Marta Sobas	Received

247-PF	WEEKEND VERSUS WEEKDAY DIAGNOSIS AND EARLY MORTALITY IN ACUTE PROMYELOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS IN THE NETHERLANDS	Avinash Dinmohamed	Received

248-PF	DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE REAL LIFE EXPERIENCE FROM THE "ITALIAN TRIVENETO REGISTRY".	Carla Fili´	Received

249-PF	PROGNOSTIC IMPACT OF SKELETAL MUSCLE ASSESSED BY COMPUTED TOMOGRAPHY SCAN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Nobuhiko Nakamura	Received

250-PF	INCIDENCE OF MARROW NEOPLASMS IN BREAST CANCER SURVIVORS: A NATIONAL POPULATION-BASED COHORT STUDY	Marie joelle Jabagi	Received

251-PF	WILMS TUMOR 1 EXPRESSION IN ACUTE MYELOID LEUKEMIA CORRELATES WITH CYTOGENETICS OR COLLABORATIVE MUTATIONS: HOKKAIDO LEUKEMIA NET STUDY	Daisuke Hidaka	Received

253-PF	HYPOMETILATING AGENTS (HMA) AS SALVAGE THERAPY IN RELAPSED OR REFRACTORY AML: AN ITALIAN 9-CENTER RETROSPECTIVE STUDY	Marica Laurino	Received

255-PF	REAL WORLD EVIDENCE ON THE BURDEN OF ILLNESS EXPERIENCED BY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SYSTEMIC MYCOSES	Anna Forsythe	Received

257-PF	AZACITIDINE FRONTLINE AND SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS. CLINICAL EXPERIENCE AND DEVELOPMENT OF RISK SCORE	Silvia Imbergamo	Received

260-PF	IMPACT OF COMORBIDITY ON DISEASE CHARACTERISTICS, TREATMENT INTENT AND OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA – A SWEDISH LYMPHOMA REGISTER STUDY	Tove Wästerlid	Received

263-PF	OVERWEIGHT LYMPHOMA PATIENTS TREATED BY ACTUAL BODY WEIGHT HAD NO EXCESS OF CHEMOTHERAPY TOXICITY: EXPERIENCE FROM TWO LARGE TRIALS	Bridgin Merron	Received

264-PF	QUALITY OF LIFE IN CUTANEOUS T-CELL LYMPHOMA SUBJECTS TREATED WITH THE ANTI-CCR4 MONOCLONAL ANTIBODY MOGAMULIZUMAB VERSUS VORINOSTAT: RESULTS FROM THE PHASE 3 MAVORIC TRIAL	Pietro Quaglino	Received

266-PF	SUBSTITUTION OF CISPLATIN FOR CARBOPLATIN OR OXALIPLATIN IN THE DHAP REGIMEN IS ASSOCIATED WITH IMPROVED SURVIVAL IN RELAPSED/REFRACTORY NON-HODGKIN´S LYMPHOMAS	Eloit Martin	Received

267-PF	VCAP-AMP-VECP VERSUS CHOP AS FIRST-LINE CHEMOTHERAPY FOR AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A PROPENSITY SCORE ANALYSIS	Shigeo Fuji	Received

269-PF	TITLE: LENALIDOMIDE PLUS R-CHOP THERAPY PROVIDES DURABLE LONG-TERM REMISSIONS IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): COMBINED ANALYSIS FROM TWO PHASE 2 TRIALS.	Alessia Castellino	Received

273-PF	MONITORING OF RHOA G17V MUTATION DURING THE COURSE OF THERAPY IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA BY QUANTITATIVE ALLELE-SPECIFIC PCR WITH LNA-MODIFIED PRIMERS	Yulia Sidorova	Received

274-PF	CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOME OF ELDERLY SYSTEMIC T/NK CELL LYMPHOMA IN A RESOURCE-LIMITED COUNTRY: THE RESULT OF THAILAND NATIONWIDE LYMPHOMA REGISTRY	Kitsada Wudhikarn	Received

275-PF	RETROSPECTIVE ANALYSIS OF PATIENTS WITH PRIMARY CENTRAL NERVOUS LYMPHOMAS TREATED WITH METHOTREXATE-BASED REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT AND TEMOZOLOMIDE MAINTENANCE	Maria Ljungqvist	Received

276-PF	RITUXIMAB, GEMCITABINE AND OXALIPLATIN (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS NOT CANDIDATES FOR HIGH-DOSE THERAPY WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). A SINGLE CENTER STUDY OF 115 PATIENTS	Clarisse Cazelles	Received

280-PF	SOLUBLE INTERLEUKIN-2 RECEPTOR AS A SURROGATE BIOMARKER OF METABOLIC TUMOR VOLUME MEASURED BY 18F-FDG PET/CT IN DIFFUSE LARGE B-CELL LYMPHOMA	Hajime Senjo	Received

285-PF	CLINICAL RESPONSE AND PHARMACOKINETICS OF BENDAMUSTINE AS A COMPONENT OF SALVAGE R-B(O)AD THERAPY FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)	Deok-Hwan Yang	Received

286-PF	OUTPATIENT SYSTEMIC HIGH-DOSE METHOTREXATE AS CNS PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Rubén Fernández-Alvarez	Received

287-PF	OUTCOME OF A 10-YEAR POPULATION-BASED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE FIRST-LINE, REFRACTORY AND RELAPSED SETTING: ´REAL-WORLD´ DATA IDENTIFY SUBGROUPS IN NEED OF NEW THERAPIES	H.T. van der Galien	Received

288-PF	LOW SUNLIGHT EXPOSURE AT TIME OF DLBCL DIAGNOSIS MAY BE ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY WOMEN	Anna Elinder Camburn	Received

290-PF	CLINICAL CHARACTERISTICS AND OUTCOMES OF BURKITT LYMPHOMA IN A DEVELOPING COUNTRY	Wellington Fernandes Da Silva Junior	Received

291-PF	AN INCREASED RISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN CHILDREN AFTER CARDIAC TRANSPLANTATION FOR CONGENITAL HEART DISEASE	Ugonna .T. Offor	Received

292-PF	IDENTIFICATION OF NOVEL MECHANISMS UNDERLYING FUNCTIONAL RESPONSE TO DRUG-INDUCED READTHROUGH OF HAEMOPHILIA B NONSENSE MUTATIONS	Mattia Ferrarese	Received

293-PF	ASSESSMENT OF IMMUNE FUNCTION BEFORE AND AFTER TREATMENT WITH RECOMBINANT FACTOR VIII FUSED WITH FC FRAGMENTS	Stephanie P´ng	Received

296-PF	PREDICTION OF INHIBITORS IN HAEMOPHILIA PATIENTS BY SCORE IN ONE CENTER	Oleksandra Stasyshyn	Received

298-PF	APPLICATION OF THE ISTH BLEEDING SCORE IN HEMOPHILIA	Naveena Fatima	Received

301-PF	PROTEIN EXPLORER IN THE CONTEXT OF OVERLAP OF BONE MARROW FAILURE DISORDERS	Ayodele Alaiya	Received

303-PF	LOW PROPORTION OF MYELOID DERIVED SUPPRESSOR CELL POPULATIONS IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA	Nikoleta Bizymi	Received

304-PF	CLINICAL SIGNIFICANCE OF PNH CLONES IN 3085 PATIENTS WITH CYTOPENIA: A LARGE SINGLE-CENTER EXPERIENCE.	Bruno Fattizzo	Received

305-PF	RA101495, A SUBCUTANEOUSLY-ADMINISTERED PEPTIDE INHIBITOR OF COMPLEMENT COMPONENT C5, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: PHASE 2 RESULTS	Anita Hill	Received

307-PF	CLINICAL AND MORPHOLOGIC PREDICTORS OF OUTCOME IN APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG	Bruno Fattizzo	Received

308-PF	A COMPARATIVE STUDY OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY AND HAPLOIDENTICAL TRANSPLANTATION FOR YOUNG SEVERE APLASTIC ANEMIA	miao chen	Received

312-PF	COMPLEMENT ACTIVATION AND EXACERBATION OF HAEMOLYSIS SECONDARY TO RESPIRATORY VIRAL INFECTIONS IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH) PATIENTS TREATED WITH ECULIZUMAB	Ioanna Lazana	Received

314-PF	THE INCIDENCE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELL CLONES IN THE NORDIC COUNTRIES	Christian Kjellander	Received

317-PF	SMG1 LOSS ENHANCES MTOR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS	Tara Roberts	Received

318-PF	TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER CHEMOIMMUNOTHERAPY AND IBRUTINIB	Luca Vincenzo Cappelli	Received

319-PF	PAPTP LEADS TO NEOPLASTIC CELL APOPTOSIS IN THE E?-TCL1 CHRONIC LYMPHOCYTIC LEUKEMIA MOUSE MODEL	Filippo Severin	Received

320-PF	OVERTIME ASSESSMENT OF EPIGENETIC PROFILES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY	Maria Tsagiopoulou	Received

322-PF	CLL-DERIVED EXOSOMES REPROGRAM THE PHOSPHOPRTEOMICS LANDSCAPE OF ENDOTHELIAL CELLS.	Lian Lipshtein	Received

323-PF	DYNAMIC REGULATION OF THE HS1/CXCR4 AXIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS	Luca Pavesi	Received

324-PF	CHRONIC LYMPHOCYTE LEUKEMIA CELLS SHARE A UNIQUE CIRCULAR RNA EXPRESSION PATTERN	Oshrat Raz	Received

325-PF	T CELL CLONAL DYNAMICS ARE ASSOCIATED WITH CLINICAL RESPONSE AFTER LENALIDOMIDE CONSOLIDATION TREATMENT IN CLL	Anastasia Hadzidimitriou	Received

327-PF	EVOLUTION OF GENOMIC ABNORMALITIES DURING CLL DISEASE COURSE IS ASSOCIATED WITH TELOMERE LENGTH CHANGES	Helena Olbertova	Received

328-PF	NOTCH1, TP53, SF3B1, ATM AND BIRC3 GENE MUTATIONS ARE ASSOCIATED WITH A WORSE OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13Q LOSSES	Ana E Rodríguez-Vicente	Received

330-PF	GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE	Michaela Spunarova	Received

331-PF	CIRCULATING SEX HORMONES AND NUCLEAR HORMONE RECEPTOR EXPRESSION ARE ASSOCIATED WITH TREATMENT-FREE SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Katrina Vanura	Received

332-PF	DESIGN AND MINION TESTING OF A NANOPORE SEQUENCING SPECIFIC GENE PANEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA	Francesco Albano	Received

333-PF	LOW CATALASE EXPRESSION CONFERS REDOX HYPERSENSITIVITY AND IDENTIFIES AN INDOLENT CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA	Maria Teresa Scupoli	Received

334-PF	STAT3 AND STAT5B MUTATIONS IN LARGE GRANULAR LYMPHOCYTES LYMPHOCYTOSIS/LEUKEMIAS: DIAGNOSTIC AND PROGNOSTIC VALUE	Noemí Muñoz-García	Received

337-PF	CG´806, A NON-COVALENT PAN-FLT3/PAN-BTK INHIBITOR, EXHIBITS UNIQUE BINDING TO WILD TYPE AND C481S MUTANT BTK AND GREATER POTENCY THAN IBRUTINIB AGAINST MALIGNANT B CELLS	Hongying Zhang	Received

341-PF	SALVAGE USE OF IBRUTINIB AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA OR MANTLE CELL LYMPHOMA : A STUDY ON BEHALF OF THE SFGM-TC AND THE EBMT	Mauricette Michallet	Received

343-PF	IBRUTINIB FOR FIRST-LINE TREATMENT OF OLDER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL): A 4-YEAR EXPERIENCE FROM THE RESONATE-2 STUDY	Jan Burger	Received

346-PF	SAFETY ANALYSIS OF VENETOCLAX AND IBRUTINIB FOR PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIRST INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIAL	Carsten U Niemann	Received

347-PF	EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: UPDATED RESULTS FROM THE NCRI RIALTO TRIAL.	Andrew Pettitt	Received

348-PF	OBINUTUZUMAB PRE-INDUCTION ABROGATES HIGH TUMOR LYSIS RISK OF VENETOCLAX IN TREATMENT NAÏVE FCR-UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PLANNED INTERIM ANALYSIS.	Mark-David Levin	Received

355-PF	A PHASE 1 DOSE ESCALATION STUDY OF ARQ 531 IN SELECTED PATIENS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES	Jennifer Woyach	Received

356-PF	EFFECTIVENESS OF IBRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN DAILY PRACTICE IN THE NETHERLANDS: A NATIONWIDE POPULATION-BASED COHORT STUDY	Lina Van Der Straten	Received

357-PF	RAPID DOSE ESCALATION OF VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH B-CELL RECEPTOR INHIBITOR THERAPY	Kristin Koenig	Received

360-PF	IMMUNOMODULATORY EFFECTS OF IFN-?LPHA ON T AND NK CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN DEEP MOLECULAR RESPONSE IDENTIFY POTENTIAL CANDIDATES FOR TREATMENT DISCONTINUATION	Massimo Breccia	Received

361-PF	IDENTIFICATION OF GENES DIFFERENTLY EXPRESSED BETWEEN BONE MARROW CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS VS. 12 MONTHS OF FIRST-LINE NILOTINIB TREATMENT	Alessandra Trojani	Received

362-PF	NK-CELLS AND LOSS OF MOLECULAR RESPONSE AFTER TKI DISCONTINUATION IN CML PATIENTS	Nikolay Kapranov	Received

364-PF	POLYMORPHISMS IN MULTIDRUG RESISTANCE TRANSPORTER GENES AFFECT THE DURATION OF MOLECULAR RESPONSE TO NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS	Federica Loscocco	Received

365-PF	MYELOID CELL POPULATION DYNAMICS IN TKI-TREATED CML	Sieghart Sopper	Received

366-PF	THE EFFECT OF PREGNANE X RECEPTOR SNP AND TKI TROUGH CONCENTRATION ON CLINIC RESPONSE AND TOXICITY AMONG CHINESE CML PATIENTS.	Zhiping Jiang	Received

370-PF	PREVALENCE AND OUTCOMES OF UNCOMMON BCR-ABL FUSION TRANSCRIPTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DATA FROM A SINGLE CENTER	Ya-Zhen Qin	Received

372-PF	VARIATION IN LIMIT OF BLANK FOR BCR-ABL1 DETECTION BETWEEN LABORATORIES IMPACTS ON SCORING OF DEEP MOLECULAR RESPONSE	Helen White	Received

373-PF	DIGITAL PCR IN PH+ CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION	Michele Malagola	Received

374-PF	FIRST INTERIM ANALYSIS OF THE RUSSIAN MULTICENTER PROSPECTIVE STUDY RU-SKI: DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND DEEP MOLECULAR RESPONSE	Ekaterina Chelysheva	Received

375-PF	RESULTS OF TREATMENT OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PREGNANCY IN ACCORDANCE WITH THE LEUKEMIC BURDEN AND TERM OF PREGNANCY (THE LET SCHEME)	Ekaterina Chelysheva	Received

376-PF	ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA IN THE TKI ERA: POPULATION BASED DATA FROM THE SWEDISH CML REGISTRY.	Anna Lübking	Received

378-PF	NILOTINIB VERSUS NILOTINIB COMBINED TO PEGYLATED-INTERFERON ALFA 2A IN FIRST-LINE CHRONIC PHASE CML PATIENTS. UPDATED INTERIM ANALYSIS OF A PHASE III TRIAL	Franck Nicolini	Received

379-PF	THE VALUE OF BCR-ABL1 QPCR LEVEL AND DOUBLING TIME (DT) TO PREDICT SUCCESSFUL TREATMENT-FREE REMISSION AFTER IMATINIB DISCONTINUATION: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB (TRAD) TRIAL	Dennis Kim	Received

380-PF	ADDRESSING THE DIAGNOSTIC GAPS IN PYRUVATE KINASE (PK) DEFICIENCY. CONSENSUS RECOMMENDATIONS ON THE DIAGNOSIS OF PK DEFICIENCY	Paola Bianchi	Received

381-PF	IMPLEMENTATION OF THE DIAGNOSTIC WORKFLOW OF HEREDITARY ANEMIAS BY USING TARGETED-NGS PANEL ANALYSIS	Roberta Russo	Received

382-PF	GENETIC MARKERS AND NEW TARGET GENES IN THE DIAGNOSIS OF RARE ANAEMIAS	Joan-Lluis Vives-Corrons	Received

387-PF	HIGH SUCCESS RATE OF TARGETED NEXT GENERATION SEQUENCING FOR THE DIAGNOSIS OF PATIENTS WITH RARE CONGENITAL ANEMIAS	Orna Steinberg-Shemer	Received

388-PF	DIAGNOSIS OF RARE CONGENITAL HEMOLYTIC ANEMIAS ENABLED BY NEXT GENERATION SEQUENCING PANEL	Elisa Fermo	Received

389-PF	NEXT GENERATION SEQUENCING FOR DIAGNOSIS OF INHERITED HEMOLYTIC ANEMIAS	Jorge Nieto	Received

390-PF	REPORT OF THE FIRST CASE OF HEREDITARY SPHEROCYTOSIS DUE TO A LARGE DELETION OF THE SPTA1 GENE	Patricia Aguilar-Martinez	Received

391-PF	CONGENITAL ERYTHROPOIETIC PORPHYRIA AS A MIMICKER OF CHRONIC HEMOLYTIC ANEMIAS IN INFANTS	Yasmine El Chazli	Received

392-PF	CLINICAL CHARACTERISTICS OF PATIENTS WITH RED CELL PYRUVATE KINASE DEFICIENCY IN GERMANY	Paraskevi Klothaki	Received

393-PF	ANTITUMOR ACTIVITY BY TEGS: ALPHA/BETA T CELLS ENGINEERED TO EXPRESS A DEFINED GAMMA/DELTA TCR IN A 3D BONE MARROW NICHE MODEL OF MULTIPLE MYELOMA	Jurgen Kuball	Received

394-PF	DUAL TARGETING STRATEGY OF ACUTE MYELOID LEUKEMIA BY ENGINEERED CYTOKINE-INDUCED KILLER CELLS COEXPRESSING AN INTERLEUKIN 3 CHIMERIC ANTIGEN RECEPTOR (CAR) AND AN ANTI-CD33 COSTIMULATORY RECEPTOR	Vincenzo Maria Perriello	Received

395-PF	SYNERGISTIC T CELL SIGNALING BY CD79A/CD40 COSTIMULATORY ENDODOMAIN ENHANCES CD19 CHIMERIC ANTIGEN RECEPTOR T CELL PROLIFERATION AND SURVIVAL	Jakrawadee Julamanee	Received

396-PF	LENALIDOMIDE AND PROGRAMMED DEATH-1 BLOCKADE SYNERGISTICALLY ENHANCES THE EFFECTS OF DENDRITIC CELL VACCINATION IN A MODEL OF MURINE MYELOMA	Je-Jung Lee	Received

397-PF	RNAI-MEDIATED SILENCING OF ENDOGENOUS TCR ENHANCES TUMOR KILLING ACTIVITY OF TCR-ENGINEERED WT1-SPECIFIC T CELLS	Diana Campillo	Received

400-PF	FIRST-LINE THERAPY WITH DONOR DERIVED HCMV-SPECIFIC T CELLS PROMOTES ANTIVIRAL IMMUNITY BY RESTORING THE QUANTITY AND FUNCTION OF RECIPIENT´S ENDOGENOUS HCMV-SPECIFIC T CELLS AFTER ALLO-HSCT	Xiangyu Zhao	Received

402-PF	THE EFFICACY AND SAFETY OF HUMANIZED CD19 CAR-T CELLS FOR RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (NHL): A PRELIMINARY REPORT	Honghui Huang	Received

403-PF	THE STUDY OF LYMPHOCYTES SUBPOPULATIONS IN PERIPHERAL BLOOD OF PATIENTS WITH AND WITHOUT GVHD PROPHYLAXIS BY MEANS OF MULTIPOTENT MESENCHYMAL STROMAL CELLS AFTER ALLOGENEIC BMT	Yulia Davydova	Received

404-PF	LIVE ATTENUATED VARICELLA ZOSTER VIRUS VACCINATION TO ADULT T-CELL LEUKEMIA/LYMPHOMA PATIENTS CAN INDUCE TUMOR SPECIFIC CELLULAR IMMUNITY.	Tatsuro Jo	Received

405-PF	PRODUCTION OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19 CELLS) IN PATIENTS WITH CD19+ RELAPSED/REFRACTORY B-CELL MALIGNANCIES USING THE CLINIMACS PRODIGY SYSTEM	Julio Delgado	Received

407-PF	EARLY GROWTH RESPONSE (EGR)-1 IS A KEY REGULATOR OF HUMAN PRIMARY BONE MARROW STROMA CELLS WITH A DUAL ROLE IN PROLIFERATION AND HEMATOPOIETIC STROMA SUPPORT FUNCTION.	Stefan Scheding	Received

410-PF	HIERARCHICALLY RELATED LINEAGE-RESTRICTED FATES BY MULTIPOTENT HEMATOPOIETIC STEM CELLS	Petter Woll	Received

414-PF	AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN CENTENARIANS AND CARDIOVASCULAR DISEASE PATIENTS: A SURVIVAL BIAS HYPOTHESIS	Luca Bertamini	Received

416-PF	ROS-DEPENDENT SELF-RENEWAL DEFECTS OF HUMAN HEMATOPOIETIC STEM CELLS AFTER EXPOSURE TO LOW DOSE OF IONIZING RADIATIONS	Marie-Laure Arcangeli	Received

417-PF	THE HISTONE CHAPERONE NAP1L3 IS REQUIRED FOR HEMATOPOIETIC STEM CELL MAINTENANCE AND DIFFERENTIATION	Gözde Turköz	Received

418-PF	THE IN VIVO EFFECT OF CHEMOTHERAPY AND CXCR4 ANTAGONISM ON AML AND T-ALL CELL MIGRATION IN THE BONE MARROW.	Delfim Duarte	Received

419-PF	PROSPECTIVELY ISOLATED BONE MARROW STROMAL CELLS FROM PATIENTS WITH HEMATOLOGICAL MALIGNANCIES DIFFER PHENOTYPICALLY AND RELATE TO DISEASE STAGE IN MGUS/MYELOMA	Stefan Scheding	Received

420-PF	CD83 IS A NEW POTENTIAL BIOMARKER AND THERAPEUTIC TARGET FOR HODGKIN LYMPHOMA	Ziduo Li	Received

422-PF	TARGETING ROR1 RECEPTOR IN CLASSICAL HODGKIN LYMPHOMA: EFFECTS ON APOPTOSIS AND PROLIFERATION AND ITS EMERGING THERAPEUTIC IMPLICATIONS	Louloudenia Velentza	Received

423-PF	TREATMENT RELATED INCIDENCE OF DISEASES OF THE CIRCULATORY SYSTEM IN PATIENTS DIAGNOSED WITH HODGKIN LYMPHOMA	Caroline Weibull	Received

425-PF	RISK OF SECOND MALIGNANCIES IN HODGKIN LYMPHOMA PATIENTS IN THE NEW MILLENNIUM: REAL WORLD EVIDENCE FROM THE SEER DATABASE	Velizar Shivarov	Received

427-PF	INTERIM- PET RESULTS FOR PROGNOSIS IN ADULTS WITH HODGKIN LYMPHOMA: A PROGNOSTIC FACTOR EXEMPLAR REVIEW (PRELIMINARY RESULTS)	Angela Aldin	Received

428-PF	DOWNREGULATION OF STATS DETERMINE POOR PROGNOSIS IN HODGKIN´S LYMPHOMA.	Stephen Ting	Received

430-PF	PAEDIATRIC HODGKIN LYMPHOMA IN VERY YOUNG PATIENTS: THE ITALIAN EXPERIENCE	Piero Farruggia	Received

432-PF	THE COMBINATION OF ALISERTIB AND ROMIDEPSIN IS A SAFE AND EFFECTIVE REGIMEN FOR RELAPSED/REFRACTORY AGGRESSIVE HODGKIN AND T-CELL LYMPHOMAS: A PHASE 1 STUDY	Paolo Strati	Received

433-PF	?SUVMAX AND ?SUVPEAK IMPROVE THE NEGATIVE PREDICTIVE VALUE OF INTERIM PET SCAN IN HODGKIN LYMPHOMA	Teresa Ribeiro	Received

434-PF	OUTCOME OF ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA IN CENTRAL SCOTLAND, UK	Mark Rafferty	Received

440-PF	AUTOLOGOUS STEM CELL TRANSPLANTATION MAY CURE FOLLICULAR LYMPHOMA PATIENTS WITH EARLY THERAPY FAILURE WHO REACH COMPLETE RESPONSE AFTER RESCUE TREATMENT IRRESPECTIVE OF PREVIOUS RITUXIAMB EXPOSURE.	Ana Jiménez Ubieto	Received

441-PF	RESULTS OF A DOSE ESCALATION STUDY OF ME-401, A SELECTIVE PI3K? INHIBITOR, IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)	John M Pagel	Received

442-PF	SHORT DIAGNOSIS TO TREATMENT INTERVAL IS ASSOCIATED WITH POOR OUTCOMES IN PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IMMUNOCHEMOTHERAPY	Michael R Clausen	Received

443-PF	NEW ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA	Takafumi Shichijo	Received

446-PF	R-ESHAP IS NOT EFFECTIVE AS SALVAGE THERAPY IN REFRACTORY FOLLICULAR LYMPHOMA: RESULTS OF A RETROSPECTIVE MULTICENTRE STUDY ON BEHALF OF GELCAB GROUP	Ana Muntañola	Received

449-PF	COMPARATIVE EFFICACY AND SAFETY OF DIFFERENT ANTIVIRAL AGENTS FOR CYTOMEGALOVIRUS PROPHYLAXIS AFTER HEMATOPOIETIC-CELL TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSES	Nico Gagelmann	Received

450-PF	CANDIDA-REACTIVE T CELLS FOR THE DIAGNOSIS OF INVASIVE CANDIDA INFECTION	Felix Koehler	Received

451-PF	TENOFOVIR VERSUS LAMIVUDINE FOR PREVENTION OF HEPATITIS B VIRUS REACTIVATION AMONG PATIENTS WITH AGGRESSIVE LYMPHOMAS UNDERGOING FRONT-LINE ANTHRACYCLINE-CONTAINING CHEMOTHERAPY	Irene Zacheo	Received

453-PF	MURCORMYCOSIS AND ASPERGILLOSIS IN ONCOHEMATOLOGICAL PATIENTS: WHAT´S THE DIFFERENCE?	Nikolay Klimko	Received

454-PF	INVASIVE FUNGAL DISEASES CAUSED BY RARE PATHOGENS IN CHILDREN WITH HEMATOLOGICAL DISEASES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CHEMOTHERAPY	Marina Olegovna Popova	Received

455-PF	INVASIVE ASPERGILLOSIS IN HAEMATOLOGICAL PATIENTS: A REVIEW OF 625 CASES	Raoul Herbrecht	Received

456-PF	DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN HIGH RISK HEMATOLOGICAL MALIGNANCY PATIENTS: PERFORMANCE OF BIOMARKERS AND CYTOKINES IN SAME DAY BLOOD AND BRONCHOALVEOLAR LAVAGE FLUID SAMPLES.	Hoenigl Martin	Received

457-PF	NEUTROPHIL EXTRACELLULAR TRAPS IMPAIR FUNGAL CLEARANCE IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS	Astrid Alflen	Received

458-PF	HEMOPHAGOCYTIC LIMPHOHISTIOCYTOSIS ASSOCIATED WITH LEISHMANIASIS: A HIDDEN PASSENGER IN ENDEMIC AREAS?	Jon Badiola	Received

460-PF	ANTIGFUNGAL DRUGS MODULATE HUMAN NEUTROPHIL ACTIVITIES IN VITRO AND IN VIVO IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Daniel Teschner	Received

461-PF	(1-3)-?-D-GLUCAN ASSAY AND AIRWAY-INVASIVE RADIOLOGICAL FINDINGS AS EARLY SIGNS OF PULMONARY ASPERGILLOSIS IN HIGH-RISK HEMATOLOGIC PATIENTS IN THE POSACONAZOLE ERA: PRELIMINARY OBSERVATIONS	Claudia Giordano	Received

462-PF	COMPARATIVE ANALYSIS OF DETECTION OF EBV SMALL NON-CODING RNA (EBER) AND MARKERS OF ACUTE EBV INFECTION AT THE ONSET OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA	Natalia Chernova	Received

463-PF	THE ROLE OF SERUM GALACTOMANNAN ASSAY IN THE MANAGEMENT OF INVASIVE MOLD INFECTIONS IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION.	Maria Esther Martinez-Muñoz	Received

464-PF	CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION	Carlos de Miguel	Received

465-PF	EPIDEMIOLOGY AND TREATMENT APPROACHES OF INVASIVE FUNGAL INFECTIONS MANAGEMENT IN HEMATOLOGICAL MALIGNANCIES: RESULTS FROM A SINGLE-CENTRE STUDY	Katarina Gluic	Received

466-PF	HERPES VIRUSES AT THE ONSET OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA. IS THERE AN ASSOCIATION?	Dmitry Tikhomirov	Received

467-PF	POST-TRANSPLANT EBSTEIN-BARR VIRAL LOAD MONITORING EXPERIENCE IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER	Mürüvvet Seda Aydin	Received

468-PF	ISAVUCONAZOLE SHORTENS THE QTC INTERVAL	Sibylle Mellinghoff	Received

469-PF	ALPHA LIPOIC ACID REDUCES THE TOXIC EFFECTS INDUCED BY IRON OVERLOAD TREATMENT: IN VITRO AND IN VIVO MODELS	Giuseppina Camiolo	Received

470-PF	A PHASE 1, PLACEBO-CONTROLLED STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING SUBCUTANEOUS DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN HEALTHY ADULTS	Eva Hortas	Received

471-PF	REPEATABILITY OF LIVER IRON CONCENTRATION MEASUREMENTS WITH MRI AND AN ARTIFICIAL NEURAL NETWORK DATA ANALYSIS SYSTEM	Tim St Pierre	Received

473-PF	IRON OVERLOAD IN RARE HEREDITARY HEMOLYTIC ANEMIA	Stephanie van Straaten	Received

474-PF	IRON OVERLOAD INCREASES OXIDATIVE STRESS AND DECREASES CLONOGENIC CAPACITY OF CELLS IN MDS PATIENTS: CAN BE RESTORED AFTER DEFERASIROX TREATMENT?	Tamara Jiménez Solas	Received

476-PF	TISSUE IRON OVERLOAD ASSESSMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Kira Lukina	Received

478-PF	A RARE CAUSE OF HEREDITARY HEMOCHROMATOSIS : COMPOUND HETEROZYGOSITY ASSOCIATING THE C282Y VARIATION WITH A PRIVATE HFE MUTATION - TWO CASES COMBINING NEW NONSENSE MUTATIONS.	Severine Cunat	Received

480-PF	SOMATIC MUTATIONS AS MARKERS OF OUTCOME AFTER AZACITIDINE TREATMENT FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTION (HSCT) IN HIGHER-RISK (HR) MDS AND LOW-BLAST COUNT ACUTE MYELOID LEUKEMIA (LBC-AML)	Giulia Falconi	Received

481-PF	SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND AZACITIDINE (AZA) IN TP53-MUTATED MYELODYSPLASTIC SYNDROMES	Nabih Maslah	Received

482-PF	GENE PANEL ANALYSIS BY NEXT GENERATION SEQUENCING FOR THE DETECTION OF CLONAL HAEMATOPOIESIS IN IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) AND MYELODYSPLASTIC SYNDROME (MDS)	Yannick Wouters	Received

485-PF	ASXL1 IS A MOLECULAR PREDICTOR IN IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE	Dong-Yeop Shin	Received

488-PF	USING PU.1 AND JUN DIMERIZATION PROTEIN 2 TRANSCRIPTION FACTOR EXPRESSION IN MYELODYSPLASTIC SYNDROMES TO PREDICT TREATMENT RESPONSE AND LEUKEMIA TRANSFORMATION	Ciro Rinaldi	Received

490-PF	A NOVEL CULTURE MODEL FOR STUDYING TERMINAL ERYTHROID DIFFERENTIATION IN PATIENTS WITH SF3B1 MUTATED MYELODYSPLASTIC SYNDROMES	Edda María Elvarsdóttir	Received

491-PF	PROGNOSTIC SIGNIFICANCE OF THE ASXL1 GENE ALTERATION IN PATIENTS WITH ISOLATED 20Q DELETION	Jana Brezinova	Received

492-PF	PARP1 EXPRESSION PROFILE AND DIVERGENT CLINICAL IMPACT IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA.	Ana María Hurtado López	Received

494-PF	MECHANISTIC CHARACTERIZATION OF HDACI MEDIATED KIT DOWNREGULATION IN SYSTEMIC MASTOCYTOSIS	Katarina Lyberg	Received

496-PF	DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION	Begoña Pedrote	Received

497-PF	CLONAL EVOLUTION IS MUCH MORE FREQUENT IN MDS AS KNOWN AS YET	Christina Ganster	Received

499-PF	ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH ERYTHROPOIESIS STIMULATING AGENTS	Juan Carlos Caballero	Received

500-PF	MOLECULAR SCORING SYSTEM INTEGRATED WITH IPSS-R IN KOREAN MYELODYSPLASTIC SYNDROME	Hee Sue Park	Received

501-PF	PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MULTILINEAGE DYSPLASIA WITH OR WITHOUT RING SIDEROBLASTS.	Abhishek Mangaonkar	Received

502-PF	CLINICAL OUTCOMES OF PATIENTS WITH MDS/MPN OVERLAP SYNDROMES	Simon Kavanagh	Received

503-PF	FLOW CYTOMETRY ANALYSIS OF ERYTHROPOIETIC MATURATION PATTERNS HELP TO DIAGNOSE AND FOLLOW-UP ERYTHROPOIETIC DYSPLASIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Despoina Violidaki	Received

506-PF	DIFFERENCES IN MUTATIONAL PROFILE AND CLONAL ARCHITECTURE OF MYELODYSPLASTIC SYNDROMES WITH ISOLATED DELETION OF 5Q, HYPERPLASTIC AND HYPOPLASTIC MYELODYSPLASTIC SYNDROMES	Francisca Hernández Mohedo	Received

507-PF	CLINICAL SIGNIFICANCE OF REDUCED EXPRESSION OF THE GENES LOCATED WITHIN COMMON DELETED REGION OF DEL(20Q) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Masayuki Shiseki	Received

508-PF	HIGH WT1 EXPRESSION LEVELS AT DIAGNOSIS PREDICTED POOR OUTCOMES OF PATIENTS PRESENTING ISOLATED THROMBOCYTOPENIA AT ONSET OF MYELODYSPLASTIC SYNDROME	Qiu-Sha Huang	Received

509-PF	ROLE OF DNA METHYLATION GENE AND TP53 MUTATIONS IN PREDICTING THE CLINICAL EFFICACY OF EPIGENETIC THERAPY IN MYELOID NEOPLASM PATIENTS - META ANALYSIS	Li Cai	Received

510-PF	THE EVALUATION OF OXIDATIVE STRESS AND IRON METABOLISM MARKERS IN MYELODYSPLASTIC SYNDROMES	Mihnea-Alexandru Gaman	Received

511-PF	MUTATIONS IN 19S PROTEASOME SUBUNITS REPRESENT A NOVEL MECHANISM OF ACQUIRED RESISTANCE TO PROTEASOME INHIBITORS IN MULTIPLE MYELOMA PATIENTS	Santiago Barrio	Received

512-PF	EXPRESSION OF P53 ISOFORMS AT MRNA LEVEL IN MULTIPLE MYELOMA: IMPLICATIONS FOR CLINICAL OUTCOME	Elizabeta De Los Angeles Rojas	Received

514-PF	ADAR1-MEDIATED-A-TO-I-EDITING IS BIOLOGICALLY AND CLINICALLY RELEVANT IN MULTIPLE MYELOMA	Phaik Ju Teoh	Received

515-PF	MOLECULAR MECHANISMS OF THE ACTIVITY OF THE NOVEL C-MYC TARGETED-COMPOUND IDP-501 IN MM	Patryk Krzeminski	Received

516-PF	SNPS ARRAY ANALYSIS OF COPY NUMBER ALTERATIONS (CNAS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS: DEFINITION OF A PROGNOSTIC RISK-CLASSIFIER.	Carolina Terragna	Received

517-PF	PEPTIDE STIMULATION OF PD-L1 SPECIFIC T CELLS NATURALLY OCCURING IN MYELOMA PATIENTS AUGMENT THE ADCC ACTIVITY OF DARATUMUMAB	Nicolai Grønne Jørgensen	Received

518-PF	NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE IN A PREDICTIVE MYELOMA IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES BIOMARKERS DETERMINING SUSCEPTIBILITY	Niamh Keane	Received

519-PF	CD26 IS A POTENTIAL THERAPEUTIC TARGET BY HUMANIZED MONOCLONAL ANTIBODY IN MULTIPLE MYELOMA	Hiroko Nishida	Received

520-PF	DNA REPAIR PROCESSES TARGET TRANSCRIBED REGION IN MULTIPLE MYELOMA	eva hortas	Received

522-PF	STUDY OF PLASMA CELL TRASCRIPTOME IN SMOLDERING MYELOMA PATIENTS IN RELATIONSHIP TO PROGRESSION TO ACTIVE MULTIPLE MYELOMA.	Paola Storti	Received

523-PF	GENOMIC CHARACTERIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA REVEALS DISTINCT PATTERNS OF DISEASE EVOLUTION	Aino-Maija Leppä	Received

524-PF	LONGITUDINAL CHROMOSOMAL ABNORMALITIES ANALYSIS IN MULTIPLE MYELOMA DISEASE PROGRESSION REVEALS CLONAL EVOLUTION AFTER THERAPY.	Stefania Oliva	Received

526-PF	RAPID AND SCALABLE GENOME-WIDE PROFILING OF CLINICALLY RELEVANT GENETIC ABERRATIONS IN MULTIPLE MYELOMA	Donat Alpar	Received

528-PF	RNA-SEQ BASED RISK STRATIFICATION IN MULTIPLE MYELOMA PATIENTS VALIDATES SKY92 AS A HIGH RISK MARKER IN THE COMMPASS TRIAL	Rowan Kuiper	Received

529-PF	MDSCS CONTRIBUTE TO CANCER STEM CELLS ACCUMULATION VIA PIRNA 823 UPREGULATION AND DE NOVO DNA METHYLATION IN MULTIPLE MYELOMA	Lisha Ai	Received

531-PF	LOW-PASS SEQUENCING OF PLASMA CELL DNA AND OF CIRCULATING CELL-FREE DNA FOR THE DETECTION OF COPY NUMBER ABERRATIONS AND EARLY RESPONSE MONITORING IN MULTIPLE MYELOMA	Barbara Dewaele	Received

532-PF	RNA-SEQ ANALYSIS UNRAVELS SPECIFIC LONG NON-CODING RNA TRANSCRIPTIONAL FINGERPRINTS IN MULTIPLE MYELOMA SUBTYPES	Elisa Taina	Received

533-PF	COMBINATION TARGETING OF SIALYLATION AND THE PROTEASOME INHIBITS TUMOR GROWTH AND INCREASES SURVIVAL IN A HUMANIZED MOUSE MULTIPLE MYELOMA MODEL	Michaela Reagan	Received

534-PF	ACTIVATION OF NFAT (NUCLEAR FACTOR OF ACTIVATED T CELLS) SIGNALING AND INDUCTION OF AUTOPHAGY CONFER BORTEZOMIB RESITSTANCE IN MULTIPLE MYELOMA	Margaret Ng	Received

535-PF	THE CONICAL AGAROSE MICROWELL ARRAY (CAMA) ENABLES 3D LONG-TERM CULTIVATION OF PRIMARY SAMPLES AND ENHANCED HIGH THROUGHPUT SCREENING FOR RATIONAL EPIGENTIC/ANTIBODY COMBINATION IN MULTIPLE MYELOMA	Stefan J. Mueller	Received

536-PF	ENHANCED CYTOTOXICITY OF MULTIPLE MYELOMA CELLS USING DARATUMUMAB IN COMBINATION WITH NK CELLS ENGINEERED TO EXPRESS HIGH-AFFINITY CD16 (F158V)	Michael O´Dwyer	Received

537-PF	IMMUNOLOGICAL PROFILING BY MASS CYTOMETRY REVEALS THAT TIM3 EXPRESSION IS REDUCED ON NK CELL SUBSETS IN NEWLY DIAGNOSED MYELOMA AND IS ASSOCIATED WITH LOSS OF NK FUNCTION AND DECREASED SURVIVAL	Frances Seymour	Received

540-PF	MDSCS PROMOTED TUMORIGENESIS OF MULTIPLE MYELOMA BOTH IN VITRO AND IN VIVO.	Lisha Ai	Received

541-PF	TARGETING THE INTERACTION OF MULTIPLE MYELOMA AND THE BONE MARROW MICROENVIRONMENT THROUGH NOVEL SMALL MOLECULES DIRECTED TO NOTCH PATHWAY	Natalia Platonova	Received

542-PF	EXPRESSION LEVELS OF THE THREE GENES CRBN, IKZF1, AND IKZF3 IN PRIMARY MULTIPLE MYELOMA CELLS AT PRE- AND POST- LENALIDOMIDE TREATMENT	Shiori Kinoshita	Received

543-PF	MYC INVOLVES MULTIPLE MYELOMA PROGRESSION BY ATTENUATING TUMOR SUPPRESSIVE FUNCTION OF TP53-MICRO RNA 34 AXIS	Yuki Murakami	Received

545-PF	TRYPTOPHAN SHORTAGE DUE TO IDO-1 EXPRESSED BY HIGH-DENSITY NEUTROPHILS INDUCE IMMUNE-SUPPRESSION AND PLASMA CELL FITNESS IN MULTIPLE MYELOMA	Alessandra Romano	Received

546-PF	CHARACTERIZATION OF ST3GAL6-AS1, A NOVEL LNCRNA DEREGULATED IN MULTIPLE MYELOMA	Cristina Vinci	Received

547-PF	MULTIPLE MYELOMA RELATED ANGIOGENESIS: ROLE OF NOTCH-JAG AXIS IN MODULATING ENDOTHELIAL CELLS BEHAVIOR	Maria Teresa Palano	Received

548-PF	ADIPORON, THE FIRST ORAL ADIPONECTIN RECEPTOR AGONIST, INHIBITS THE PROLIFERATION OF MYELOMA CELLS VIA THE AMPK / MTOR /AUTOPHAGY SIGNALING PATHWAY	Shujuan Wang	Received

549-PF	CLINICAL RELEVANCE OF LONG NON CODING RNA IN MULTIPLE MYELOMA: RETROSPECTIVE MONOCENTRIC STUDY	Valeria Ferla	Received

550-PF	DRUG SENSITIVITY SCREENING IN MULTIPLE MYELOMA (MM) FOR PRECISION CANCER THERAPY	Deepak Balaji Thimiri Govinda Raj	Received

552-PF	DISCOVERY BLOOD PLASMA PROTEOMICS IN ELUCIDATING BIOMARKERS TO DISTINGUISH ONSET OF LETHAL MULTIPLE MYELOMA IN PREMALIGNANT MGUS	Luz Yurany Moreno	Received

553-PF	VARIABLES PREDCITVE OF POOR PROGNOSIS IN PATIENTS WITH MAYO STAGE 1 SYSTEMIC LIGHT CHAIN AMYLOIDOSIS	Faye Sharpley	Received

554-PF	SINGLE AGENT CARFILZOMIB PROLONGS PFS FOLLOWING TRIPLET THERAPY WITH CYCLOPHOSPHAMIDE & DEXAMETHASONE FOR FIRST RELAPSE/PRIMARY REFRACTORY MULTIPLE MYELOMA: PHASE 2 MUKFIVE STUDY, SECOND ANALYSIS	Kwee Yong	Received

556-PF	LEVOFLOXACIN PROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA REDUCES FEBRILE EPISODES AND DEATH WITHOUT INCREASING HEALTHCARE ASSOCIATED INFECTIONS: RESULTS FROM THE TEAMM TRIAL	Stella Bowcock	Received

557-PF	PROGNOSTIC SIGNIFICANCE OF MAGNETIC RESONANCE IMAGING BEFORE AND AFTER UPFRONT AUTOLOGOUS TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA – A SUBGROUP ANALYSIS FROM THE GMMG MM5 PHASE III TRIAL	Maximilian Merz	Received

560-PF	CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)	Francesca Gay	Received

566-PF	TIME TO PLATEAU AS A PREDICTOR OF SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA	Patrick Mellors	Received

568-PF	PRE-TREATMENT CD38 EXPRESSION LEVELS IN MYELOMA CELLS AND CD38-POSITIVE REGULATORY T CELLS AFFECT THE RESPONSE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TO TREATMENT WITH DARATUMUMAB	Akihiro Kitadate	Received

569-PF	UPDATED RESULTS OF A PHASE II STUDY WITH CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) FOR NEWLY DIAGNOSED TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS.	Alessandra Larocca	Received

570-PF	DEVELOPMENT OF A PREDICTIVE MODEL OF MULTIPLE MYELOMA (MM) PATIENT OUTCOMES BASED ON TREATMENT (TX) SEQUENCING USING DATA FROM THE CONNECT® MM PATIENT REGISTRY	Sundar Jagannath	Received

575-PF	SMOLDERING MYELOMA AFTER IMWG UPDATE: FACTORS PREDICTIVE OF EVOLUTION, ROLE OF ADVANCED IMAGING AND OF CLINICAL JUDGEMENT. A REAL-LIFE RETROSPECTIVE EXPERIENCE	Lorenza Torti	Received

577-PF	CLINICAL CHARACTERISTICS AND OUTCOMES OF OLIGOSECRETORY AND NON-SECRETORY MULTIPLE MYELOMA	Efstathios Kastritis	Received

578-PF	SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN INDEPENDENTLY PREDICTS FOR RENAL RESPONSE IN MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT	Efstathios Kastritis	Received

580-PF	LONG-TERM RESULTS FROM THE HOVON-50 STUDY: IMPROVED SURVIVAL WITH THALIDOMIDE BEFORE AND AFTER TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA	Niels Van De Donk	Received

584-PF	UPDATE OF THE PHASE 2 STUDY OF CARFILZOMIB, THALIDOMIDE, AND LOW-DOSE DEXAMETHASONE AS INDUCTION/CONSOLIDATION IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA, CARTHADEX TRIAL	Ruth Wester	Received

585-PF	CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED PATIENTS WITH AL AMYLOIDOSIS WITH "NON-MEASURABLE" FREE LIGHT CHAINS: PROGNOSTIC IMPLICATIONS AND RESPONSE EVALUATION	Efstathios Kastritis	Received

587-PF	ABSENCE OF BONE DISEASE IS AN INDEPENDENT FAVORABLE PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN SYMPTOMATIC MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS	Eirini Katodritou	Received

588-PF	CORRELATION OF 11C-METHIONINE-PET AND FDG-PET IN MULTIPLE MYELOMA WITH MRD ASSESSMENT BY FLOWCYTOMETRY.	María Marcos	Received

589-PF	TRANSLOCATION (14;16) POSITIVE MULTIPLE MYELOMA PATIENTS: CLINICAL FEATURES AND SURVIVAL OUTCOMES OF A HIGH-RISK POPULATION.	Roberto Mina	Received

590-PF	THE SWEDISH MYELOMA REGISTRY: INCREASED SURVIVAL OVER TIME IN PATIENTS 66-80 YEARS OLD, DIAGNOSED 2008-2016	Cecilie Hveding Blimark	Received

591-PF	18F-FDG PET/CT AT DIAGNOSIS IS USEFUL FOR DETERMINING THE SURVIVAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA CLASSIFIED AS STAGE II WITH THE REVISED INTERNATIONAL STAGING SYSTEM	Sung-Hoon Jung	Received

593-PF	IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA – DATA FROM THE CZECH REGISTRY OF MONOCLONAL GAMMOPATHIES	Jiri Minarik	Received

594-PF	ALLOGRAFT IN MULTIPLE MYELOMA: EXPERIENCE OF MULTIPLE MYELOMA GIMEMA LAZIO GROUP	Federico Vozella	Received

596-PF	MP0250 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: FIRST SAFETY AND EARLY EFFICACY ANALYSIS OF MP0250-CP201	Eva Hortas	Received

597-PF	STATIN USE IMPROVES MYELOMA-SPECIFIC SURVIVAL AND IS SAFE TO USE IN LYMPHOMA: A POPULATION-BASED STUDY OF 20,464 PATIENTS WITH LYMPHOID MALIGNANCIES DIAGNOSED IN SWEDEN 2007-2013	Elsa Brånvall	Received

598-PF	A PROSPECTIVE ANALYSIS ON THE FREQUENCY AND PREDICTIVE VALUE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY FLOW CYTOMETRY AND PET-CT IMAGING AMONG MYELOMA PATIENTS ON/OFF MAINTENANCE	Meral Beksac	Received

599-PF	EARLY RELAPSE IS A POWERFUL INDEPENDENT NEGATIVE PREDICTOR FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS	Eirini Katodritou	Received

600-PF	SENSIVITY AND CLINICAL VALUE OF POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY AND WHOLE BODY MAGNETIC RESONANCE IMAGING TO ASSESS BONE DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA.	Elena Fernandez-Poveda	Received

601-PF	ANTI-SLAMF7 ANTIBODY SUPPRESSES FIBROCYTE DIFFERENTIATION AS A POTENT THERAPEUTIC AGENT FOR MYELOFIBROSIS	Takaaki Maekawa	Received

603-PF	PHARMACOLOGIC TARGETING OF NEOPLASTIC STEM CELLS IN HUMAN MAST CELL LEUKEMIA	Gregor Eisenwort	Received

604-PF	THE PHENOTYPIC PROFILE OF ACUTE MYELOID LEUKEMIA SECONDARY TO CHRONIC MYELOPROLIFERATIVE NEOPLASMS: RESULTS OF A MULTI-CENTER STUDY	Francesco Mannelli	Received

606-PF	PATIENT-DERIVED INDUCED PLURIPOTENT STEM CELLS REVEALED CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE 2 AS A POTENTIAL THERAPEUTIC TARGET OF MYELOFIBROSIS	Masashi Miyauchi	Received

607-PF	MUTATIONAL MECHANISMS OF EZH2 INACTIVATION IN MYELOID NEOPLASMS	Andrew Chase	Received

609-PF	SDF1 ?LPHA-INDUCED CHEMOTAXIS OF JAK2-V617F POSITIVE CELLS IS DEPENDENT ON BRUTON´S TYROSINE KINASE AND PHOSPHOLIPASE C GAMMA 1	Subbaiah Chary Nimmagadda	Received

613-PF	DURABILITY OF SPLEEN RESPONSE MAY AFFECT OUTCOME OF RUXOLITINIB-TREATED PATIENTS WITH MYELOFIBROSIS: RESULTS FROM A MULTICENTRE STUDY ON 284 PATIENTS	Francesca Palandri	Received

614-PF	DEVELOPMENT OF A PROGNOSTICALLY RELEVANT ´CACHEXIA INDEX´ IN PRIMARY MYELOFIBROSIS USING SERUM ALBUMIN AND CHOLESTEROL LEVELS	Maura Nicolosi	Received

615-PF	PATIENTS WITH LOW JAK2 ALLELE BURDEN HAVE A HIGH RATE OF CO-OCCURRENT CALR MUTATIONS BEARING AN EFFECT ON DISEASE PHENOTYPE IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS.	Barbara Mora	Received

617-PF	HIGH RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AFTER TERMINATION OF ANTICOAGULATION	Kai Wille	Received

619-PF	MUTATIONAL LANDSCAPE AND ITS IMPACT ON OUTCOMES IN ACCELERATED AND BLAST PHASE OF MYELOPROLIFERATIVE NEOPLASMS	Caroline Mcnamara	Received

620-PF	SAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON ?LPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS – A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY	Stine Ulrik Mikkelsen	Received

624-PF	PRIMARY THERAPY AND SURVIVAL IN PRIMARY MYELOFIBROSIS: A NATIONWIDE POPULATION-BASED ANALYSIS AMONG 1,445 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 2001 AND 2015	Avinash Dinmohamed	Received

629-PF	RELATIONSHIP BETWEEN MPN PAIN AND EMOTIONAL HEALTH: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP	Robyn Scherber	Received

630-PF	ANALYSIS OF IPSET-THROMBOSIS VS R-IPSET-THROMBOSIS IN A POPULATION OF 776 ESSENTIAL THROMBOCYTHEMIA PATIENTS - A MULTICENTER RETROSPECTIVE STUDY.	Marta Sobas	Received

631-PF	SKEWED RATIO BETWEEN TYPE 1 AND TYPE 2 CALR MUTATIONS IN ESSENTIAL THROMBOCYTOSIS PATIENTS WITH CONCOMITANT JAK2 V617F MUTATION	Anni Aggerholm	Received

632-PF	CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN: NEW INSIGHTS INTO A NOVEL AND STILL ENIGMATIC ENTITY	Aliki Xochelli	Received

634-PF	MYC-MEDIATED DOWNREGULATION OF MIR-150 CONTRIBUTES TO THE TRANSFORMATION OF FOLLICULAR LYMPHOMA BY UPREGULATING FOXP1 LEVELS	Katerina Musilova	Received

635-PF	THE AXL TYROSINE KINASE INHIBITOR, BGB324, INDUCES CELL DEATH IN MANTLE CELL LYMPHOMA	Pascal Gelebart	Received

640-PF	ELEVATED SERUM IL-8, IL-10, IL-22, AND MCP-1 ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOMES IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA	Jun Ho Yi	Received

641-PF	BIOMARKER ANALYSES OF PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR RICHTER´S TRANSFORMATION TREATED WITH IBRUTINIB + NIVOLUMAB IN THE PHASE 1/2A LYM1002 STUDY	Anas Younes	Received

642-PF	SYSTEMS BIOLOGY ANALYSIS OF RESPONSIVENESS OF NON-HODGKIN LYMPHOMA B-CELL LINES TO CD37 TARGETING RADIOIMMUNOTHERAPY	Sebastian Patzke	Received

643-PF	CBL-MZ IS NOT A SINGLE BIOLOGICAL ENTITY: EVIDENCE FROM GENOMIC ANALYSIS AND PROLONGED CLINICAL FOLLOW UP	Jonathan Strefford	Received

644-PF	HETEROGENEOUS MUTATIONS AT RHOA EXON 2 REVEALED BY TARGETED SEQUENCING OF CELL FREE DNA AND PERIPHERAL BLOOD MONONUCLEAR CELL DNA IN PERIPHERAL T-CELL LYMPHOMA	Simon D. Wagner	Received

645-PF	PROGRAMMED DEATH-1 PATHWAY UP-REGULATION BY LENALIDOMIDE IN ACTIVATED LOW-GRADE LYMPHOMA CELLS	Fortunato Morabito	Received

647-PF	INCORPORATION OF GENE EXPRESSION PROFILING FOR CELL-OF-ORIGIN DETERMINATION USING FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE SECTIONS IN ROUTINE WORK-UP OF DIFFUSE LARGE B-CELL LYMPHOMA CASES	Ryan S. Robetorye	Received

648-PF	DIFFUSE LARGE B CELL LYMPHOMA WITH CONCORDANT BONE MARROW INVOLVEMENT. UTILITY OF FLOW CYTOMETRY, CLINICAL AND BIOLOGICAL EVALUATION.	Lucia Morais	Received

651-PF	IMMUNOGLOBULIN KAPPA DELETING ELEMENT (IGK-KDE) REARRANGEMENTS AS POSSIBLE TARGET FOR MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN MANTLE CELL LYMPHOMA (MCL)	Irene Della Starza	Received

652-PF	CIRCULATING MICRORNAS (MIRNAS) IN ITP PATIENTS BEFORE AND AFTER TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS)–DIAGNOSTIC AND PROGNOSTIC VALUE	Lamya Garabet	Received

656-PF	PREEMPTIVE RITUXIMAB HAS A FAVORABLE BENEFIT-RISK BALANCE IN THE PREVENTION OF LONG-TERM RELAPSES IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA	Matthieu Jestin	Received

662-PF	EXTENDED FOLLOW UP OF PATIENTS TREATED IN THE RITUXIMAB AS SECOND-LINE TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA – THE RITP STUDY	Waleed Ghanima	Received

664-PF	PREDICTORS OF SUCCESS FOR SPLENECTOMY IN CHILDHOOD AUTOIMMUNE CYTOPENIA	Nathalie Aladjidi	Received

665-PF	SHORT- AND LONG-TERM ELTROMBOPAG FOR THE TREATMENT OF INHERITED THROMBOCYTOPENIAS: A PHASE 2 CLINICAL TRIAL	Carlo Zaninetti	Received

669-PF	MYH9-RELATED THROMBOCYTOPENIA: FOUR NOVEL VARIANTS AFFECTING THE TAIL DOMAIN OF THE NON-MUSCLE MYOSIN HEAVY CHAIN IIA ASSOCIATE WITH A MILD CLINICAL EVOLUTION OF THE DISEASE	Carlo Zaninetti	Received

672-PF	PERFORMANCE OF THE ISTH BLEEDING ASSESSMENT TOOL IN PREDICTING THE PRESENCE OF INHERITED PLATELET FUNCTION DISORDERS	Maaike Blaauwgeers	Received

673-PF	SPLENECTOMY IN COMPARISON WITH RITUXIMAB AS A SECOND LINE TREATMENT FOR RELAPSED OR REFRACTORY ITP	Ana Boban	Received

676-PF	PREDICTIVE FACTORS FOR SUCCESSFUL SPLENECTOMY OUTCOME – SYSTEMATIC REVIEW	Mirjana Mitrovic	Received

678-PF	PLATELET COUNT EVOLUTION AS A PREDICTOR OF OUTCOME AFTER RITUXIMAB TREATMENT IN CHRONIC IMMUNE THROMBOCYTOPENIA	Shixuan Wang	Received

680-PF	LONG-TERM EFFICACY AND SAFETY OF ROMIPLOSTIM FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA	Sergey Semochkin	Received

681-PF	ITP SECONDARY TO ALEMTUZUMAB-INDUCED RENAL TRANSPLANT: OUTCOME OF 31 PATIENTS	Elisa Lucchini	Received

682-PF	AN OBSERVATIONAL, NON-INTERVENTIONAL CLINICAL PRACTICE STUDY OF ROMIPLOSTIM IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) – PLATON FINAL RESULTS	Georgi Mihaylov	Received

683-PF	COMBINED/CONCOMITANT THERAPY FOR RAPID RECOVERY IN PATIENTS WITH REFRACTORY/RECURRENT IMMUNE THROMBOCYTOPENIA (ITP) AND MODERATE/SEVERE BLEEDING: AN OBSERVATIONAL STUDY	Mariasanta Napolitano	Received

687-PF	QUALITY OF LIFE IN NEWLY DIAGNOSED AND RELAPSED DANISH MULTIPLE MYELOMA PATIENTS - A NATIONAL LONGITUDINAL STUDY OF DANISH MYELOMA STUDY GROUP	Lene Kongsgaard Nielsen	Received

688-PF	A QUALITATIVE ANALYSIS OF PSYCHOLOGICAL HEALTH MEASURES IN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA AFTER BEING TREATED WITH BFM-ALL PROTOCOLS	Asif Iqbal	Received

690-PF	DETERMINANTS AND CLINICAL SIGNIFICANCE OF MUSCULOSKELETAL SYMPTOMS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE	Ana Zelic Kerep	Received

692-PF	RAPID AND COMPREHENSIVE GENOMIC CHARACTERIZATION OF HEMATOLOGICAL MALIGNANCIES USING A HYBRID-CAPTURE TARGETED SEQUENCING PANEL	Michaela Gruber	Received

693-PF	UNTANGLING HOSPITALIZATIONS IN SYSTEMIC AMYLOIDOSIS: PATIENT CHARACTERISTICS, ECONOMIC COST AND CLINICAL OUTCOMES	Tiffany P. Quock	Received

694-PF	ERECTILE DISFUNCTION IN HEMATOLOGICAL MALIGNANCIES	Frosina Krstanoska	Received

696-PF	RELEVANT REDUCTION OF POMALIDOMIDE-RELATED NEUTROPENIA BY INTENSIVE USE OF MYELOID GROWTH FACTOR	MARINA SILVIA PARISI	Received

697-PF	REAL WORLD EVIDENCE BASED COST-EFFECTIVENESS ANALYSES (CEA) OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA (CML) IN CHINA	Yongping Song	Received

698-PF	LIVING AND COPING WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A QUALITATIVE STUDY OF GREEK PATIENTS´ EXPERIENCES ON BEHALF OF ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL	Aliki Xochelli	Received

699-PF	COMPARISON OF THE PAPER-BASED AND ELECTRONIC VERSION OF A NEW PATIENT-REPORTED OUTCOME MEASURE IN HAEMATOLOGICAL MALIGNANCY FOR USE IN CLINICAL PRACTICE, HM-PRO: AN EQUIVALENCE STUDY	Pushpendra Goswami	Received

703-PF	ERN-EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK IN RARE HEMATOLOGICAL DISEASES. 1ST YEAR OF IMPLEMENTATION	María del Mar Mañú Pereira	Received

704-PF	PALLIATIVE CARE INDICATION IN NON-HODGKIN´S LYMPHOMA PATIENTS: A COMPARISON TO SOLID TUMOR PATIENTS	Lucia Morais	Received

706-PF	DIAGNOSIS DISCLOSURE IN PATIENTS WITH HEMATOLOGICAL CANCERS IN INDIA	Chepsy Cherian Philip	Received

707-PF	NATIONAL EVALUATION OF QUALITY OF CARE DURING THE 5 FIRST YEARS OF LIFE FOR CHILDREN DIAGNOSED BY THE NEWBORN SICKLE CELL SCREENING PROGRAMME IN FRANCE: RESULTS OF EVADREP STUDY	Isabelle Thuret	Received

708-PF	VISUAL CORTEX CHANGES IN CHILDREN WITH SICKLE CELL DISEASE: A MULTIMODAL MRI STUDY	Raffaella Colombatti	Received

714-PF	ACCESS TO EMERGENCY DEPARTMENT AND IDENTIFICATION OF SUBJECTS WITH SICKLE CELL DISEASE AND OTHER HEMOGLOBINOPATHIES IN REFUGEES	Lucia De Franceschi	Received

715-PF	AN ANALYSIS OF PAIN CRISIS PATTERNS IN DIFFERENT GEOGRAPHIC REGIONS OF THE WORLD: ANALYSIS FROM THE CASIRE STUDY.	Raffaella Colombatti	Received

717-PF	COULD LIVER INVOLVEMENT BE EARLY DETECTED IN SICKLE CELL DISEASE?	Marta Bortolotti	Received

718-PF	SAFETY AND IMPROVED SUSTAINED RESPONSE RATES IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE TREATED WITH IBRUTINIB: 1-YEAR UPDATE OF A PHASE 1B/2 STUDY	Edmund Waller	Received

719-PF	SINGLE CORD BLOOD UNIT PLUS THIRD PARTY DONOR CELLS (HAPLO-CORD) TRANSPLANTATION COMPARED TO ADULT UNRELATED DONORS IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE CASE-CONTROL STUDY	Guiomar Bautista Carrascosa	Received

720-PF	CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION AND SALVAGE ASCT IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA WITH FIRST RELAPSE AFTER UPFRONT ASCT	Henrik Gregersen	Received

721-PF	THE ROLE OF COLLATERAL RELATED DONORS IN HAPLOIDENTICAL HEMATOPOIETIC TRANSPLANTATION: A COMPARATIVE STUDY BETWEEN COLLATERAL RELATED DONORS AND PARENTAL DONORS.	Xiao-Dong Mo	Received

722-PF	EFFICACY OF BONE MARROW DERIVED MSC FOR STEROID REFRACTORY ACUTE GVHD ASSOCIATES WITH AGE AND A DEFINED MOLECULAR PROFILE OF MSC DONORS	Lotte Van Der Wagen	Received

723-PF	PROGNOSTIC INDEX FOR PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WHO UNDERWENT HEMATOPOIETIC CELL TRANSPLANTATION: A KSGCT MULTICENTER ANALYSIS	Takayoshi Tachibana	Received

725-PF	TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: INCIDENCE, PROGNOSTIC FACTORS, MORBIDITY AND MORTALITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	Eleni Gavriilaki	Received

726-PF	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN THE OUTPATIENT SETTING: A SINGLE CENTER EXPERIENCE OF 924 CONSECUTIVE TRANSPLANTS	Salwa Saadeh	Received

731-PF	COMPARISON OF MOBILIZED PERIPHERAL BLOOD STEM CELLS VERSUS BONE MARROW HAPLOIDENTICAL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: A RETROSPECTIVE STUDY OF SFGM-TC IN 176 PATIENTS	Nathalie Jacque	Received

732-PF	G-CSF/ATG-BASED REGIMEN IS SUPERIOR TO PTCY-BASED REGIMEN IN TERMS OF ENGRAFTMENT AFTER MYELOABLATIVE HAPLOIDENTICAL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES	Xiao-Jun Huang	Received

733-PF	BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II MULTICENTRIC STUDY.	Giuseppe Visani	Received

734-PF	A HIGH PRE-TREATMENT BONE MARROW CD34+/CD38- CELL BURDEN IN PATIENTS WITH MYELODYSPLASTIC SYNDROME IS A PROGNOSTIC FACTOR FOR DISEASE PROGRESSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Madlen Jentzsch	Received

735-PF	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOID NEOPLASMS: RETROSPECTIVE STUDY OF SFGM-TC	Daniel Jaimes Albornoz	Received

736-PF	A PHASE I/II STUDY OF PEGYLATED-INTERFERON-2ALPHA FOR RELAPSED HAEMATOLOGICAL MALIGNANCY AFTER ALLOGENEIC HAEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION	Andrea Henden	Received

737-PF	OUTCOME OF MESENCHYMAL STROMAL CELL TREATMENT IN CHRONIC GVHD PREDICTED BY THYMIC FUNCTION: A PHASE II CLINICAL STUDY	Erik Boberg	Received

738-PF	IMPAIRED BONE MARROW ENDOTHELIAL PROGENITOR CELLS ARE INVOLVED IN THE PATHOGENESIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOTRANSPLANT	Xie-Na Cao	Received

739-PF	PHASE II PROSPECTIVE STUDY OF DIFFERENT ATG DOSING IN ADDITION TO STANDARD HAPLOIDENTICAL TRANSPLANT CONDITIONING WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY)	Mona Hassanein	Received

740-PF	EXTENSIVE TELOMERE SHORTENING IN MONONUCLEAR CELLS IS ASSOCIATED WITH INFERIOR OVERALL SURVIVAL AFTER NON-MYELOABLATIVE ALLO-HCT	Jens Helby Petersen	Received

741-PF	G-CSF MOBILIZED MACROPHAGES POLARIZATION MAY PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Qi Wen	Received

742-PF	INTERFERON-? IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH T(8;21) ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xiao-Dong Mo	Received

743-PF	EFFICACY AND SAFETY OF AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN ELDERLY MULTIPLE MYELOMA (MM) PATIENTS AGED = 65 YEARS: A SINGLE CENTRE EXPERIENCE	Philip Campbell	Received

744-PF	PD-1 CONTRIBUTES TO THE DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION	Eunkyoung You	Received

745-PF	A PHASE 1 PILOT STUDY OF ULTRA-LOW DOSE IL-2 AS GVHD PROPHYLAXIS IN HAPLO-IDENTICAL STEM CELL TRANSPLANTATION	Sawa Ito	Received

746-PF	THE IMPACT OF CMV REACTIVATION ON HSCT OUTCOMES IN CHILDREN WITH MALIGNANCIES: A 13 YEARS SINGLE CENTER EXPERIENCE	Francesco Baccelli	Received

747-PF	A REAL-LIFE SINGLE CENTER RETROSPECTIVE ANALYSIS TO EVALUATE EBMT RISK INDEX AS A PROGNOSTIC FACTOR IN PEDIATRIC HSCT	Alessandro Di Gangi	Received

749-PF	THE HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX IN THE CONTEXT OF AUTOLOGOUS STEM CELL TRANSPLANTATION CAN PREDICTS CLINICAL OUTCOMES.	Alexandra Martínez-Roca	Received

750-PF	INTRA-BONE CORD BLOOD TRANSPLANT WITHOUT IN-VIVO T-CELL DEPLETION: RESULTS IN 12 PATIENTS.	Elisabetta Xue	Received

751-PF	HEMATOPOIETIC REGENERATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION WITH ACTUAL BODY WEIGHT BASED DOSING OF CONDITIONING CHEMOTHERAPY	David Fuchs	Received

752-PF	IMPACT OF MIXED CHIMERISM IN T REGULATORY CELLS ON RELAPSE RATE IN ACUTE LEUKEMIA PATIENTS AFTER ALLO-HSCT	Darya Dubnyak	Received

753-PF	REDUCED-INTENSITY CONDITIONING WITH FLUDARABINE AND BUSULFAN VERSUS FLUDARABINE AND MELPHALAN FOR T DEPLETED ALLOGENEIC TRANSPLANT IN MYELOID MALIGNANCIES: AN EXPERIENCE OF A TERTIARY CENTRE	Marta Sofia Lopes	Received

755-PF	A MESENCHYMAL STROMAL CELL (MSC)-DERIVED COMBINATION OF CXCL5 AND ANTI-CCL24 IS SYNERGISTIC AND SUPERIOR TO MSC AND CYCLOSPORINE FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE	Xiubo Fan	Received

756-PF	GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR AND LEUKEMIC STEM CELL LINES FROM TRANSGENIC MICE	Eszter Doma	Received

759-PF	EX-VIVO GENERATED HUMAN CORD BLOOD MYELOID-DERIVED SUPPRESSOR CELLS (HCB-MDSCS) ATTENUATE MURINE CHRONIC GRAFT-VERSUS-HOST DISEASES	Chang-Ki Min	Received

760-PF	EFFICACY OF DEFIBROTIDE FOR PREVENTION AND TREATMENT OF ACUTE GRAFT-VERSUS HOST DISEASE IN A FULLY MHC-MISMATCHED MURINE MODEL OF ALLOGENEIC BONE MARROW TRANSPLANTATION	David García-Bernal	Received

763-PF	LONG-TERM LONGITUDINAL PROSPECTIVE CMR STUDY IN PATIENTS WITH THALASSEMIA MAJOR	Antonella Meloni	Received

764-PF	CEREBROVASCULAR DISEASE IN BETA-THALASSEMIA: NOT A DISEASE RELATED COMPLICATION?	Immacolata Tartaglione	Received

766-PF	DAILY ALTERNATING DEFERASIROX AND DEFERIPRONE AS NEW THERAPEUTIC SCHEME FOR IRON OVERLOAD IN UNTREATABLE TRANSFUSION DIPENDENT THALASSEMIA PATIENTS	Valeria Pinto	Received

767-PF	DENOSUMAB EFFECTS ON SERUM LEVELS OF THE BONE MORPHOGENIC PROTEINS ANTAGONIST NOGGIN IN PATIENTS WITH BETA-THALASSEMIA MAJOR AND OSTEOPOROSIS	Evangelos Terpos	Received

769-PF	COMPARAISON OF MORBIDITIES BETWEEN NON TRANSFUSION AND TRANSFUSION DEPENDENT THALASSEMIA PATIENTS OLDER THAN 45 YEARS	Alessia Marcon	Received

770-PF	A RANDOMIZED, CONTROLLED, PHASE III STUDY TO EVALUATE S-303/GLUTATHIONE PATHOGEN-INACTIVATED RED BLOOD CELLS IN THALASSEMIA MAJOR PATIENTS (SPARC)	Yesim Aydinok	Received

771-PF	EVALUATION OF VASCULAR HEALTH OF E-BETA THALASSEMIA PATIENTS: EFFECT OF IRON OVERLOAD	Dibyendu De	Received

772-PF	CHRONIC HEPATITIS C VIRUS INFECTION IN THALASSEMIA MAJOR: A NEW CARDIOVASCULAR RISK FACTOR?	Antonella Meloni	Received

774-PF	EFFICACY AND SAFETY OF RESVERATROL, AN ORAL HBF AUGMENTING AGENT, IN PATIENTS WITH BETA THALASSEMIA INTERMEDIA	Mehran Karimi	Received

775-PF	HYPERURICEMIA, URINE URIC EXCRETION AND ITS COMPLICATIONS IN THALASSEMIA PATIENTS	Adisak Tantiworawit	Received

778-PF	ANTICOAGULATION IN THE OBESE - A PROSPECTIVE REGISTRY	Eva Hortas	Received

779-PF	CHARACTERISTICS OF PLATELET COUNT AND SIZE AND DIAGNOSTIC ACCURACY OF MEAN PLATELET VOLUME IN PATIENTS WITH VENOUS THROMBOEMBOLISM. A SYSTEMATIC REVIEW AND META-ANALYSIS	Houshang A. Shemirani	Received

781-PF	SEASONAL VARIATION IN PULMONARY EMBOLISM BUT NOT DEEP VEIN THROMBOSIS INCIDENCE: A KOREAN NATIONWIDE VENOUS THROMBOEMBOLISM EPIDEMIOLOGY STUDY	Junshik Hong	Received

783-PF	TROMBOSIS IN LYMPHOMA, INCIDENCE, RISK FACTORS AND MANAGEMENT.	Virginia Pradillo	Received

784-PF	PLATELET HYPERREACTIVITY AND POSTOPERATIVE VENOUS THROMBOEMBOLISM IN KNEE REPLACEMENT ARTHROPLASTY	Jimyung Kim	Received

785-PF	THROMBOEMBOLISM IN CHILDREN WITH CANCER; A RETROSPECTIVE MULTICENTER STUDY IN KOREA	Hyoung Soo Choi	Received

786-PF	A RETROSPECTIVE ANALYSIS OF UTILISATION OF DIRECT ORAL ANTICOAGULANT LEVELS FROM A TERTIARY HAEMATOLOGY CENTRE	Nicholas Denny	Received

787-PF	LONG- TERM MANAGEMENT OF RECURRENT VENOUS THROMBOEMBOLISM IN BLOOD CANCER PATIENTS AT HIGH BLEEDING RISK.	Mariasanta Napolitano	Received

788-PF	A MULTICENTER EXPERIENCE WITH IDARUCIZUMAB "IN REAL WORLD" AS REVERSAL ANTICOAGULATION OF DABIGATRÁN	Marta Villalba Montaner	Received

790-PF	A TERTIARY INSTITUTION BLOOD BANK EXPERIENCE AFTER THE IMPLEMENTATION OF A UNIFIED NATIONAL MASSIVE TRANSFUSION PROTOCOL (MTP) IN SINGAPORE.	Chun-Tsu Lee	Received

792-PF	RED CELL TRANSFUSION THRESHOLDS IN PATIENTS RECEIVING INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA	Amy Trottier	Received

793-PF	DEVELOPMENT OF HUMANIZED MOUSE MODELS TO EVALUATE AND PREVENT MOTHER-TO-CHILD HTLV-1 TRANSMISSIONS	Takuo Mizukami	Received

794-PF	A DESCRIPTIVE STUDY OF TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI) IN THE CANARY ISLANDS.	Cynthia Acosta Fleitas	Received

796-PF	TEN YEAR EXPERIENCE OF RED BLOOD CELL TRANSFUSION ADEQUACY INDEX AS PART OF PATIENT BLOOD MANAGEMENT PROGRAM.	Gustavo de Carvalho Duarte	Received

797-PF	A 3-PART DIFF POCT CELL ANALYZER AT THE HEMATO-ONCOLOGY WARD FOR CLINICAL DECISION MAKING OF PLATELET TRANSFUSION AND CHEMOTHERAPY	Nele Van den Eede	Received

798-PF	EVALUATION OF OXYGEN TRANSPORT OF BLOOD IN PATIENTS WITH ANEMIA ON THE BACKGROUND OF THE RED BLOOD CELLS TRANSFUSIONS	Nikolay Romanenko	Received

896-PS	INFLAMED BM-MSCS HIGHLY ATTRACT TEL-AML1+ PRE-LEUKEMIC CELLS AND PROVIDE A SUSTAINING NICHE FOR THEIR EMERGENCE	Linda Beneforti	Received

897-PS	TRANSLATOME ANALYSIS REVEALS ALTERED SERINE METABOLISM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Kim Kampen	Received

898-PS	MIR-497~195 CLUSTER IS ASSOCIATED WITH FAVORABLE OUTCOME AND HAS A TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	Elena Boldrin	Received

899-PS	MICRORNA-142 IS AN ESSENTIAL REGULATOR OF B CELL DEVELOPMENT AND MALIGNANT TRANSFORMATION	Wei-Le Wang	Received

900-PS	AN ESSENTIAL ROLE OF LCK IN T-ALL CELL PROLIFERATION AND SURVIVAL	Yuzhe Shi	Received

901-PS	TITLE: PROGNOSTIC IMPACT OF THE BCR/ABL1-LIKE SIGNATURE IN ADULT B-LINEAGE ALL. FIRST ANALYSIS OF THE GIMEMA LAL1913 PROTOCOL	Sabina Chiaretti	Received

902-PS	CHARACTERIZATION OF PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH DNA METHYLATION STATUS	Shunsuke Kimura	Received

903-PS	THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL	Malwine Pogodzinski	Received

904-PS	HUMAN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA DEVELOPS HYPOXIA-RELATED CHEMORESISTANCE THROUGH HIF1? AND MTOR PATHWAY INTERACTIONS	Lucine Fahy	Received

905-PS	METABOLOMIC ANALYSIS REVEALS CEREBROSPINAL FLUID CREATINE AND XANTHINE CONCENTRATIONS AS POTENTIAL BIOMARKERS FOR CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKAEMIA	Antony Cousins	Received

906-PS	CLONAL EVOLUTION OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS FROM DIAGNOSIS TO RELAPSE	Shumaila Sayyab	Received

907-PS	REFINED DETECTION AND PHASING OF STRUCTURAL ABERRATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA WITH LINKED-READ WHOLE GENOME SEQUENCING	Yanara Marincevic-Zuniga	Received

908-PS	AMPLICON-BASED NGS AS A TOOL FOR THE IDENTIFICATION OF NEW MARKERS WITH POOR PROGNOSIS IN B-ALL	Adrian Montaño	Received

909-PS	EXPLORING THE GENOMIC DIVERSITY OF AYA AND ADULT HIGH-RISK B-ALL CASES BY MRNA SEQUENCING	Susan L Heatley	Received

911-PS	"TRIPLE NEGATIVE" ACUTE GENE EXPRESSION CLUSTERING IDENTIFY NEW ADULT LYMPHOBLASTIC LEUKEMIA SUBGROUPS	Anna Ferrari	Received

912-PS	MOLECULAR PROFILE REFINES THE MRD-BASED PROGNOSTIC ASSESSMENT IN ADULTS WITH PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Jordi Ribera	Received

915-PS	COHESIN GENES MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA	Grazia Fazio	Received

916-PS	EVALUATION OF SAMPLE QUALITY AND CREATION OF DATABASES FOR FOLLOW-UP ASSESSMENT OF BLAST INFILTRATION AT DAY +15 IN CHILDHOOD B CELL ACUTE LYMPHOBLASTIC LEUKEMIA.	Pablo Manresa	Received

918-PS	PROGNOSTIC VALUE OF IKZF1 DELETIONS ON THE UKALL14 TRIAL; SIGNIFICANT ROLE OF BCR-ABL1 STATUS	Rachel Mitchell	Received

919-PS	FIRST RESULTS OF NEW GIMEMA TRIAL LAL1913 FOR ADULT PATIENTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH- ALL)	Renato Bassan	Received

920-PS	LOW MIR-151 AND MIR-451 LEVELS IN BONE MARROW AT DIAGNOSIS IS CONFIRMED AS A PROGNOSTIC FACTOR FOR RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE AIEOP 2000 CLINICAL TRIAL	Jennifer Yarden	Received

921-PS	THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	Virginia Rodriguez Martinez	Received

922-PS	NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL	Yves Chalandon	Received

923-PS	PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MLL REARRANGEMENT SHOW A DISTINCTIVE EXPRESSION PATTERN OF HISTONE DEACETYLASES	Nerea Vega-Garcia	Received

924-PS	PROTEOLYTIC L-ASPARAGINASE DEGRADATION AS A MECHANISM FOR NON-ANTIBODY-RELATED DRUG INACTIVATION	Justyna Walenciak	Received

926-PS	EXTRAMEDULLARY LATE RELAPSES IN ATYPICAL SITES OF ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (AIEOP)	Giovanna Giagnuolo	Received

927-PS	INCIDENCE AND OUTCOME OF RELAPSES IN YOUNG ADULTS (18-60 YR) WITH PH--POSITIVE ALLTREATED WITH IMATINIB, CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (PETHEMA ALLPH08 TRIAL)	Josep Maria Ribera	Received

929-PS	IDENTIFICATION OF BCR-ABL-LIKE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY REAL-TIME PCR	Grigory Tsaur	Received

931-PS	THE PROGNOSIS FOR PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WHO WERE INELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE TKI ERA.	Akio Shigematsu	Received

933-PS	ENHANCING MANAGEMENT OF PH+ ALL BY MONITORING WITH AN ANALYTICALLY VALIDATED MULTIPLEX ASSAY FOR BCR-ABL1 MINOR BREAKPOINT (E1A2) WITH HIGHLY SENSITIVE DETECTION OF 1:40,000 (0.0025% OR 4.6 LOGS)	Justin Brown	Received

934-PS	THE RISK OF DEVELOPING HEPATIC TOXICITY FROM PEGYLATED-ASPARAGINASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS HIGHLY AFFECTED BY CONCOMITANT MEDICATIONS	Paola Minetto	Received

935-PS	CELL OF ORIGIN INFLUENCES DISEASE AGGRESSIVENESS AND CHEMOTHERAPY RESISTANCE IN A MOUSE MODEL OF MLL-AF9 REARRANGED ACUTE MYELOID LEUKEMIA	Chi Huu Nguyen	Received

936-PS	PLASMA PROTEOME IN PATIENTS WITH LEUKEMIA AND LYMPHOMA REVEALS MAJOR DIFFERENCES RELATED TO HEMOSTASIS, INFLAMMATION AND STROMA	Anna Eriksson	Received

940-PS	GENOMIC CHARACTERIZATION OF DIAGNOSTIC AND REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA SAMPLES THROUGH A NEXT GENERATION SEQUENCING (NGS) PANEL OF 62 GENES	Diego Carbonell	Received

942-PS	SYNERGISTIC INHIBITORY EFFECT OF HYDROXYUREA AND DECITABINE ON THE PROLIFERATION OF AML CELLS	Konstantin Byrgazov	Received

943-PS	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA USING MULTIPARAMETRIC FLOW CYTOMETRY IS HIGHLY PREDICTIVE OF OUTCOME	Chinmayee Kakirde	Received

944-PS	EXPRESSION OF CD25 FLUCTUATES IN THE LEUKEMIC STEM CELL POPULATION OF CD25-POSITIVE AML	Yuki Kageyama	Received

945-PS	INTEGRIN ALPHA 7 EXPRESSION IS ASSOCIATED WITH PHENOTYPE AND GROWTH OF ACUTE MYELOGENOUS LEUKEMIA	Nobuhiko Kobayashi	Received

946-PS	THE ROLE OF STAT3? IN ACUTE MYELOID LEUKEMIA	Petra Aigner	Received

947-PS	DISSECTING INTRA-TUMOR HETEROGENEITY IN ACUTE MYELOID LEUKEMIA THROUGH LEUKEMIA STEM CELL-ASSOCIATED MIRNA SIGNATURES AND SINGLE-CELL RNA TRANSCRIPTIONAL PROFILING	Matteo Maria Naldini	Received

950-PS	TARGETED THERAPY FOR AML EXPRESSING SOMATIC OR GERMLINE MUTATION IN RUNX1	Kapil Bhalla	Received

952-PS	PHOSPHO-PROFILING LINKING AML-BIOLOGY AND RESPONSE PREDICTION IN PEDIATRIC MYELOID LEUKEMIA	Michaela Prchal-Murphy	Received

953-PS	TOWARDS IMPROVING OF SURVIVAL IN AML BY REPURPOSING EXISTING DRUGS AS NOVEL SAMHD1 INHIBITORS	Nikolaos Tsesmetzis	Received

954-PS	GENOMIC-DRIVEN AND FUNCTIONAL ALTERATIONS IN ENERGY, AMINO ACID AND LIPID METABOLISM IN ACUTE MYELOID LEUKEMIA BLASTS AND STEM PROGENITOR CELLS	Giorgia Simonetti	Received

955-PS	THE CALCIUM BINDING PROTEIN S100A8/S100A9 COMPLEX IS ASSOCIATED WITH DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA	Minxia Liu	Received

959-PS	IDENTIFICATION OF GENE COPY NUMBER ABERRATIONS AS PROGNOSTIC MARKERS OF SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS BY EXOME SEQUENCING OF LEUKEMIA DNA IN THE MAYO CLINIC AML EPIDEMIOLOGY COHORT	Yan Asmann	Received

961-PS	ACUTE MYELOID LEUKEMIA INDUCED TRANSFORMATION OF THE HUMAN BONE MARROW MICROENVIRONMENT PREDICTS CLINICAL OUTCOME	Yiyang Chen	Received

962-PS	IMMUNOPHENOTYPIC PROFILING OF LEUKEMIC STEM CELLS TO TRACK FLT3-ITD POSITIVE, CHEMO-RESISTANT CLONES IN ACUTE MYELOID LEUKEMIA	Tiziana Ottone	Received

964-PS	MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)	Orietta Spinelli	Received

966-PS	FURTHER EVIDENCE FOR GPR56, BUT NOT CLL-1 (CLEC12A) AS A MARKER FOR LEUKEMIC STEM CELLS IN CD34-POSITIVE ACUTE MYELOID LEUKEMIA	Shruti Daga	Received

967-PS	MOLECULAR ABNORMALITIES IN THERAPY-RELATED ACUTE MYELOID LEUKEMIAS	Gueorgui Balatzenko	Received

968-PS	CD123 REDIRECTED NK92 CELLS FOR ACUTE MYELOID LEUKEMIA	Li Zhou	Received

969-PS	THE DIFFERENTIAL EXPRESSION OF DNMT3A SPLICE VARIANTS AND THEIR PROGNOSTIC RELEVANCE IN ACUTE MYELOID LEUKEMIA	Stefanie Beinicke	Received

972-PS	CANDIDATE FDA-APPROVED DRUGS THAT MAY MIMIC HOXA CLUSTER DELETION IN MLL-AF9 LEUKEMIA.	Laura Kettyle	Received

974-PS	MUTATIONAL LANDSCAPE OF RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA	Licia Iaccarino	Received

976-PS	VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML	Kim R. Kampen	Received

978-PS	SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.	Davide Lazzarotto	Received

979-PS	CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Haiyan Liu	Received

985-PS	AN EVALUATION OF CONTROL REGIMENS IN A GROUP OF HIGH RISK OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FROM TWO COOPERATIVE GROUPS: DATA FROM THE UK NCRI AND DUTCH HOVON STUDIES	Robert Hills	Received

986-PS	TP53 ALTERATIONS AND MONOSOMAL KARYOTYPE IN OLDER UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH DECITABINE	Heiko Becker	Received

987-PS	IDENTIFYING A GENETICALLY DEFINED RISK GROUP OF PEDIATRIC AML PATIENTS THAT CANNOT BE RESCUED AT ALL AFTER THE FAILURE OF THE FIRST LINE TREATMENT	Naghmeh Niktoreh	Received

988-PS	A PHASE II STUDY OF THE AURORA A KINASE INHIBITOR ALISERTIB COMBINED WITH 73 INDUCTION CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA	eva hortas	Received

990-PS	NATIONAL EARLY WARNING SCORE (NEWS), QUICK SEQUENTIAL (SEPSIS-RELATED) ORGAN FAILURE ASSESSMENT (QSOFA) AND MICROBIOLOGICAL EVALUATION IN FEBRILE NEUTROPENIA OF ACUTE MYELOID LEUKEMIA	Barbara Nicolino	Received

991-PS	COMPARISON BETWEEN MULTIPARAMETRIC FLOW CYTOMETRY AND RT-QPCR ASSAY IN EVALUATING MINIMAL RESIDUAL DISEASE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IN NPM1 ACUTE MYELOID LEUKEMIA	Chiara Caprioli	Received

992-PS	MRD STATUS AT TRANSPLANTATION IN SECOND OR THIRD CR IS THE STRONGEST FACTOR AFFECTING THE PROBABILITY OF RELAPSE IN AML PATIENTS	Fabio Guolo	Received

994-PS	CELL-FREE DNA MONITORING OF MINIMAL RESIDUAL DISEASE IN AML USING A TARGETED NGS GENE PANEL	Zhiyi Xie	Received

995-PS	INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)	Betul Oran	Received

996-PS	CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION.	Philippe Rousselot	Received

999-PS	CLADRIBINE ADDED TO STANDARD INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKAEMIA, 4-YEAR EXPERIENCES FROM SLOVENIA	Saša Anžej Doma	Received

1001-PS	FLUDARABINE, HIGH DOSE CYTARABINE AND IDARUBICIN-BASED INDUCTION (FLAI) IS HIGHLY EFFECTIVE IN AML WITH MUTATED NPM1 WITH CONCOMITANT FLT3-ITD MUTATION IRRESPECTIVELY OF FLT3-ITD ALLELIC BURDEN	Paola Minetto	Received

1002-PS	CLINICAL CHARACTERISTICS AND PROGNOSIS OF 34 CASES OF ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION AND MLL GENE REARRANGEMENT	Jian Ouyang	Received

1003-PS	PROGNOSTIC RELEVANCE OF FLT3, NPM1, DNMT3A, IDH1/2 GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS	Ekaterina Motyko	Received

1004-PS	IMPACT OF BCL2 AND ABCG2 OVEREXPRESSION IN ACUTE MYELOID LEUKEMIA	Mario Tiribelli	Received

1005-PS	ABSOLUTE LYMPHOCYTE COUNT RECOVERY AFTER INDUCTION REMISSION THERAPY IS A STRONG PREDICTOR OF OVERALL SURVIVAL IN ADULT ACUTE MYELOID LEUKAEMIA	Joana Infante	Received

1006-PS	TYROSINE KINASE INHIBITORS (TKI) IN RELAPSED/REFRACTORY (RR) PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) CONFER BETTER SURVIVAL THAN CHEMOTHERAPY, DUE TO A BETTER SAFETY PROFILE.	Giovanni Marconi	Received

1007-PS	ADDITION OF BORTEZOMIB TO AML-LIKE TREATMENT FOLLOWED BY NMA ALLO-SCT IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM	Elisabeth Reuben Tolley	Received

1008-PS	BLAST TRANSFORMATION IN MYELODYSPLASTIC AND MYELOPROLIFERATIVE NEOPLASMS - SIMILARITIES AND DIFFERENCES - A REVIEW OF 100 CASES	Milan Jagurinoski	Received

1009-PS	QUALITY OF LIFE IN ACUTE LEUKEMIA PATIENTS WITH COMORBID ISCHEMIC HEART DISEASE	Tetiana Lymanets	Received

1012-PS	TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI	Carlo Visco	Received

1014-PS	EXTRACELLULAR CIRCULATING DNA IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: BIOLOGICAL CORRELATES AND PROGNOSTIC IMPACT	Dino Dujmovic	Received

1016-PS	LENALIDOMIDE PLUS BENDAMUSTINE-RITUXIMAB DOES NOT OVERCOME THE ADVERSE IMPACT OF TP53 MUTATIONS IN MANTLE CELL LYMPHOMA	Christian Winther Eskelund	Received

1017-PS	OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)	Robert Pytlik	Received

1018-PS	WOMEN WITH DIFFUSE LARGE B CELL LYMPHOMA BENEFIT MORE FROM RITUXIMAB-CONTAINING CHEMOTHERAPY	Huai-Hsuan Huang	Received

1019-PS	HIGH RISK AGGRESSIVE B-CELL LYMPHOMAS IDENTIFIED BY FISH: A MULTICENTRIC RETROSPECTIVE STUDY FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI	Maria Chiara Tisi	Received

1020-PS	RITUXIMAB, BENDAMUSTINE AND CYTARABINE (R-BAC) IN PATIENTS WITH RELAPSED-REFRACTORY AGGRESSIVE B- CELL LYMPHOMA	Maria Chiara Tisi	Received

1021-PS	A PROPENSITY SCORE ANALYSIS SHOWS THAT RITUXIMAB DOSE-ADJUSTED EPOCH IMPROVES PROGRESSION-FREE SURVIVAL OF YOUNG PATIENTS AFFECTED BY DOUBLE EXPRESSOR DIFFUSE LARGE B -CELL LYMPHOMAS	Anna Guidetti	Received

1024-PS	EXCELLENT OUTCOMES OF OLDER PATIENTS WITH PCNSL USING R-MPV/ARA-C IMMUNOCHEMOTHERAPY WITHOUT WHOLE BRAIN RADIOTHERAPY (WBRT)	Maciej Tatarczuch	Received

1025-PS	FIRST REPORT ON A SUCCESSFUL SCREENING PROGRAM FOR MYC REARRANGEMENTS AND A PROSPECTIVE CLINICAL TRIAL BASED ON MYC REARRANGEMENT IN NEWLY DIAGNOSED DLBCL PATIENTS IN THE NETHERLANDS	Martine Chamuleau	Received

1026-PS	A NOVEL IMMUNOHISTOCHEMICAL PROGNOSTIC SCORE BASED ON MYC, BCL2 AND BCL6 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RETROSPECTIVE ANALYSIS OF DE NOVO DLBCL TREATED WITH RITUXIMAB-CHOP	Mattia Novo	Received

1027-PS	ASSESSMENT OF BONE MARROW INFILTRATION AND MINIMAL RESIDUAL DISEASE BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	M Baile	Received

1028-PS	ON THE APPLICABILITY OF RHOA GLY17VAL POINT MUTATION TESTING FOR A DIFFERENTIAL DIAGNOSIS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA	Yulia Sidorova	Received

1029-PS	THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13	Annalisa Chiappella	Received

1031-PS	GLOBAL LONGITUDINAL STRAIN (2D-GLS) IN LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY +/- MEDIASTINAL RADIOTHERAPY: EARLY SUBCLINICAL CARDIOTOXICITY IN THE CARDIOCARE PROSPECTIVE OBSERVATIONAL STUDY.	Barbara Botto	Received

1033-PS	ARE OUTCOMES IMPROVING IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER? A RETROSPECTIVE ANALYSIS OF THE LAST 10 YEARS	Nicholas Denny	Received

1035-PS	COMPARISON OF R-CHOP, R-CVP, CHOP, AND CVP FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN TAIWAN: A POPULATION-BASED STUDY, 2009-2013	Huai-Hsuan Huang	Received

1036-PS	HIGH INCIDENCE OF CARDIOMYOPATHY IN PATIENTS RECEIVING CHOEP14 - POSSIBLE SYNERGISTIC CARDIOTOXICITY OF DOSE-DENSE DOXORUBICIN AND ETOPOSIDE	Igor Aurer	Received

1037-PS	PROGNOSTIC IMPACT OF SITES OF EXTRANODAL INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA	Norihito Inoue	Received

1038-PS	LIPOSOMAL DOXORUBICIN IN AGGRESSIVE B CELL LYMPHOMA SHOWS SIMILAR EFFICACY TO THE CONVENTIONAL FORMULATION: LONG TERM RESULTS FROM A RETROSPECTIVE COHORT STUDY	Ana García-Noblejas	Received

1040-PS	THE IMPACT OF DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS ON SURVIVAL OUTCOMES IN 131 NEWLY DIAGNOSED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA	Gaiane Tumian	Received

1043-PS	AN AUDIT OF THE USE OF PROTHROMBIN COMPLEX CONCENTRATION	Samantha Bonney	Received

1044-PS	HAEMOSTATIC ABNORMALITIES OR DEFECTS IN GREEK PATIENTS WITH GAUCHER DISEASE	VERONIKI KOMNINAKA	Received

1045-PS	THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS	Mehmet Baysal	Received

1047-PS	CONGENITAL FXIII DEFICIENCY IN PAKISTAN	Munira Borhany	Received

1048-PS	DISSEMINATED INTRAVASCULAR COAGULATION SCORING IN CHILDREN WITH ACUTE LEUKEMIA: IS THERE A SIMPLER AND ECONOMICAL ALTERNATIVE?	Yasmine El Chazli	Received

1049-PS	EFFECT OF THROMBOELASTOGRAPHY DEFINED COAGULOPATHY IN TRAUMATIC BRAIN INJURY	Dibyendu De	Received

1050-PS	ASSESSMENT AT DIAGNOSIS OF 200 PATIENTS WITH A PNH CLONE OR GPI-DEFICIENT CELLS =0.01% ENROLLED IN A NATION-WIDE MULTICENTRIC PROSPECTIVE OBSERVATIONAL STUDY	Magali Le Garff-Tavernier	Received

1051-PS	ASSOCIATION OF AUTOPHAGY-RELATED GENE 5 VARIANTS WITH ACQUIRED APLASTIC ANEMIA IN HAN-CHINESE POPULATION	Yahong You	Received

1053-PS	CLINICAL EFFICACY OF THERAPIES FOR TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A RETROSPECTIVE COHORT STUDY IN MULTIPLE HOSPITALS	Guangsheng He	Received

1054-PS	IDIOPATHIC NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY	Piero Farruggia	Received

1055-PS	DYNAMICS OF CMV AND EBV LOADS AFTER IMMUNOSUPPRESSIVE TREATMENT WITH RABBIT ATG AND CYCLOSPORINE IN ADULT APLASTIC ANEMIA: A PROSPECTIVE OBSERVATIONAL STUDY	Sung-Soo Park	Received

1057-PS	SCREENING FOR TELOMERE DISEASE IS IMPORTANT TO IMPROVE THE OUTCOME OF HSCT IN PEDIATRIC PATIENTS SUFFERING FROM SEVERE APLASTIC ANEMIA.	Iris Nederlof	Received

1058-PS	RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CONGENITAL BONE MARROW FAILURE SYNDROMES: SINGLE CENTER EXPERIENCE WITH FOCUS ON TCR ??+/CD19+ DEPLETION	Zhanna Shekhovtsova	Received

1059-PS	REACTIVATION OF HEPATITIS B VIRUS INFECTION IN APLASTIC ANEMIA PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY	Guangsheng He	Received

1060-PS	ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: COMBINATION OF CYCLOSPORINE A AND CORTICOSTEROIDS PRODUCE BETTER CR	Guangsheng He	Received

1061-PS	MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES	Jiali Huo	Received

1064-PS	OPTIMIZING MRD RESPONSE ASSESSMENT USING HIGH-SENSITIVITY PERIPHERAL BLOOD MONITORING DURING TREATMENT WITH IBRUTINIB COMBINED WITH OBINUTUZUMAB OR VENETOCLAX IN CLL .	Andy C. Rawstron	Received

1066-PS	HIGH CD9 EXPRESSION IS ASSOCIATED WITH THE MYD88 L265P MUTATION AND REDUCED FAILURE-FREE SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA	Jennifer R. Brown	Received

1068-PS	SELECTIVE CHK1 INHIBITOR MU380 EXHIBITS SINGLE-AGENT ACTIVITY AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH TP53 MUTATIONS	Miroslav Boudny	Received

1069-PS	PI3K INHIBITORS INHIBIT TUMOR MICROENVIRONMENT (TME) REGULATION OF PROGRAMMED DEATH-1 (PD1) AND PDL1/2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A POTENTIAL APPROACH TO OVERCOME TUMOR-INDUCED TOLERANCE	Fortunato Morabito	Received

1070-PS	PEMBROLIZUMAB (PEM) ACTIVITY IN CLL IS IMMUNE TO TUMOR MICROENVIRONMENTAL (TME) STIMULI	Fortunato Morabito	Received

1071-PS	DUAL MTOR KINASE INHIBITORS SYNERGIZE WITH IBRUTINIB TO INDUCE CLL APOPTOSIS, AND OVERCOME BCR- AND STROMAL-MEDIATED SURVIVAL ADVANTAGES CONFERRED IN THE MICROENVIRONMENT	Michael William Moles	Received

1074-PS	NEXT-GENERATION SEQUENCING AND CRISPR/CAS9 APPLICATION TO ELUCIDATE THE IMPLICATIONS OF TP53 MUTATIONS IN DEL(13Q) CHRONIC LYMPHOCYTIC LEUKEMIA	Miguel Quijada-Álamo	Received

1076-PS	ANALYSIS OF LOCUS-SPECIFIC LINE-1 AND ALU ELEMENT DNA METHYLATION REVEALS NOVEL EARLY EPIGENETIC CHANGES IN CHRONIC LYMPHOCYTIC LEUKAEMIA	Timothy Barrow	Received

1078-PS	DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION.	Amaro Taylor-Weiner	Received

1079-PS	TRACKING THE MINOR CLONES IN OLIGOCLONAL CHRONIC LYMPHOCYTIC LEUKEMIA USING HIGH-THROUGHPUT IMMUNOPROFILING	Kamila Stranska	Received

1080-PS	SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A NEW DIAGNOSTIC AND BIOLOGICAL CHALLENGE?	Anastasia Athanasiadou	Received

1081-PS	HIGHER RESPONSIVENESS OF CLL CELLS TO B-CELL RECEPTOR STIMULATION IS ASSOCIATED WITH REDUCED EXPRESSION OF INHIBITORY MOLECULES OF THE NF-?B PATHWAY	Ruud WJ Meijers	Received

1082-PS	COMPARISON OF CELLULAR AND CELL-FREE DNA FOR THE DETECTION AND MONITORING OF BTK MUTATED CLL CLONES IN PATIENTS WITH SUBSEQUENT THERAPY AFTER IBRUTINIB FAILURE	Wiebke Schier	Received

1084-PS	HIGH SET ALPHA TO SET BETA ISOFORM EXPRESSION IS ASSOCIATED WITH INFERIOR OUTCOMES AND DISCRIMINATES FAVORABLE RISK IN TWO INDEPENDENT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) COHORTS	Danielle Brander	Received

1087-PS	DISTINCT DNA METHYLATION PROFILES IN DIFFERENT CYTOGENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE INTRIGUING CASE OF TRISOMY 12	Maria Tsagiopoulou	Received

1089-PS	BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA	Miguel Quijada-Álamo	Received

1090-PS	MASS CYTOMETRY REVEALED LEUKEMIC MICROENVIRONMENT COMPLEXITY: IMPLICATIONS FOR IMMUNOTHERAPY IN A MOUSE MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA	Etienne Moussay	Received

1091-PS	CD20 IS A DIRECT REGULATOR OF B-CELL RECEPTOR SIGNALING IN THE MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA	Gabriela Pavlasova	Received

1092-PS	ROLE OF MTORC1 IN NORMAL HAEMOPOIESIS AND LEUKAEMOGENESIS	Natasha Malik	Received

1093-PS	FIRST-IN-CLASS ORAL TYROSINE KINASE INHIBITOR (KAN0439834) TARGETING ROR1 INDUCED SIGNIFICANT APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS	Mohammad Hojjat-Farsangi	Received

1094-PS	PROGNOSTIC IMPACT OF POSITIVE MINIMAL RESIDUAL DISEASE (MRD) BELOW THE THRESHOLD OF 0.01% IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS AFTER IMMUNOCHEMOTHERAPY: STUDY OF A DATASET FROM 3 FILO TRIALS	Rémi Letestu	Received

1095-PS	EVALUATION OF THE INCIDENCE, RISK FACTORS, AND MANAGEMENT OF HYPERTENSION IN PATIENTS RECEIVING IBRUTINIB FOR HEMATOLOGIC MALIGNANCIES	Farrukh Awan	Received

1097-PS	SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 27 NEW CASES FROM THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) INTERNATIONAL REGISTRY	Ilaria Del Giudice	Received

1099-PS	SURVIVAL CONTINUES TO INCREASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS AMONG 19,131 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 1989 AND 2015	Lina Van Der Straten	Received

1100-PS	PROGNOSTICATION AND FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: A CONTEMPORARY, NATIONWIDE, POPULATION-BASED ANALYSIS AMONG 1,677 PATIENTS DIAGNOSED IN THE NETHERLANDS	Lina Van Der Straten	Received

1101-PS	"IMMUNO-FLOW-FISH": HIGH THROUGHPUT FLUORESCENCE IN SITU HYBRIDISATION OF PHENOTYPED CHRONIC LYMPHOCYTIC LEUKAEMIA BY IMAGING FLOW CYTOMETRY FOR CLINICAL APPLICATION	Wendy Erber	Received

1102-PS	EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA	Darima Badmazhapova	Received

1103-PS	IDENTIFICATION OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT HIGH RISK OF INFECTION OR TREATMENT THROUGH MACHINE LEARNING ALGORITHMS	Carsten U Niemann	Received

1105-PS	T-LARGE GRANULAR LYMPHOCYTIC (T-LGL) LEUKEMIA: A LONG-TERM STUDY ON 51 PATIENTS-COULD WE CONFINE THE USE OF THE TERM "LEUKEMIA"?	Xanthi Yiakoumis	Received

1106-PS	FLOW CYTOMETRY AND PCR-BASED T-CELL CLONALITY TESTING FOR DISCRIMINATING BETWEEN REACTIVE AND NEOPLASTIC PROLIFERATION OF LARGE GRANULAR LYMPHOCYTES	Natalia Chernova	Received

1107-PS	A US BASED SURVEY: THE EXPERIENCES AND PERSPECTIVES OF 1147 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	Brian Koffman	Received

1108-PS	CHRONIC LYMPHOCYTIC LEUKEMIA IN ICELAND: A NATION-WIDE EPIDEMIOLOGY STUDY FROM 2003 TO 2016	Hrafn Hliddal Thorvaldsson	Received

1109-PS	ENRICHMENT OF ASXL1 PATHOGENIC VARIANTS AMONG PRIMARY REFRACTORY CML PATIENTS	Kristin Ayoola Gustafsson	Received

1110-PS	THE PIVOTAL ROLE OF INSULIN-LIKE GROWTH FACTOR PATHWAY AS A THERAPEUTIC TARGET IN ABL TYROSINE KINASE INHIBITOR RESISTANT LEUKEMIA CELLS	Seiichi Okabe	Received

1112-PS	THE UNCOVERING OF A BCR-ABL1 TYROSINE KINASE-INDEPENDENT SIGNATURE REVEALS NEW POTENTIAL THERAPEUTIC TARGETS IN CHRONIC MYELOID LEUKAEMIA STEM CELLS	Eduardo Gomez-Castaneda	Received

1113-PS	OPTIMAL TIME POINT FOR BCR-ABL1 KD MUTATION ANALYSIS IN CML PATIENTS; BASED ON 2013 ELN GUIDELINE	Young Rok Do	Received

1115-PS	WT1 ANALYSIS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS	Sabrina Coluzzi	Received

1116-PS	DIGITAL DROPLET PCR MAY BETTER IDENTIFY CANDIDATES FOR TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA REGARDLESS OF MEDIAN TREATMENT DURATION	Gioia Colafigli	Received

1117-PS	FREQUENCY OF TYPICAL AND ATYPICAL FUSION TRANSCRIPTS IN PATIENTS WITH BCR-ABL1-POSITIVE LEUKEMIAS – A SINGLE INSTITUTION STUDY	Gueorgui Balatzenko	Received

1118-PS	PATIENT-SPECIFIC BCR-ABL1 GENOMIC FUSION ANALYSIS OF MINIMAL RESIDUAL DISEASE OF CML PATIENTS ELIGIBLE FOR TKI STOPPING SIGNIFICANTLY OUTPERFORMED MRNA DETECTION EITHER BY QPCR OR DIGITAL PCR	Katerina Machova Polakova	Received

1119-PS	TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE	Sukjoong Oh	Received

1120-PS	TWO YEARS OF THERAPY WITH MATINIB GENERICS IN CHRONIC MYELOID LEUKEMIA; A REPORT FROM THE POLISH ADULT LEUKEMIA GROUP (PALG) IMATINIB GENERICS REGISTRY	Tomasz Sacha	Received

1121-PS	MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA	Clémence Loiseau	Received

1122-PS	PONATINIB 15 MG DAILY, COMBINING EFFICACY AND TOLERABILITY. A RETROSPECTIVE SURVEY IN ITALY.	Gianni Binotto	Received

1124-PS	CARDIOVASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS IN REAL-LIFE PRACTICE. IDENTIFICATION OF RISK FACTORS AND ROLE OF PROPHYLAXIS	Giovanni Caocci	Received

1126-PS	PEG-INTERFERON ?LPHA 2B CAN IMPROVE MOLECULAR RECURRENCES IN THE TREATMENT-FREE REMISSION; A PILOT STUDY WITH 18-MONTH FOLLOW-UP	Manuel Ayala	Received

1128-PS	CHRONIC MYELOID LEUKEMIA ITALIAN MULTICENTER OBSERVATIONAL STUDY (CML-IT-MOS): ANALYSIS OF CLINICAL CHARACTERISTICS OF 1330 CML PATIENTS TREATED IN REAL-LIFE IN 66 ITALIAN CENTERS OF THE GIMEMA GROUP	Eva Hortas	Received

1129-PS	IMATINIB STOP STUDY FEASIBLE TO JAPANESE CLINICAL SETTING.	Kensuke Usuki	Received

1132-PS	DENSITY, HETEROGENEITY AND DEFORMABILITY OF RED CELLS AS MARKERS OF CLINICAL SEVERITY IN HEREDITARY SPHEROCYTOSIS	Richard van Wijk	Received

1133-PS	GAU-PED STUDY: UPDATE ON RESULTS AND LONG-TERM OUTCOME OF PATIENTS WITH GAUCHER DISEASE DIAGNOSED THROUGH A PAEDIATRIC ALGORITHM	William Morello	Received

1136-PS	COMBINED EMA-BINDING TEST AND OSMOTIC GRADIANT EKTACYTOMETRY SIGNIFICANTLY IMPROVE THE LABORATORY DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS	Andreas Glenthøj	Received

1138-PS	PREVALENCE AND CLINICAL SIGNIFICANCE OF SMALL PNH CLONES IN PATIENTS WITH PRIMARY AUTOIMMUNE HEMOLYTIC ANEMIA	Bruno Fattizzo	Received

1140-PS	THE ESTABLISHMENT OF SD RAT MODEL AND HISTOPATHOLOGICAL STUDY OF IMMUNE HEMOLYTIC DISEASE INDUCED BY ANTIBODY.	Sai Yan	Received

1142-PS	ORGAN INVOLVEMENT IN RARE HEREDITARY HEMOLYTIC ANEMIA	Stephanie Van Straaten	Received

1143-PS	SUCCESSFUL TREATMENT OF MEGALOBLASTIC ANEMIA WITH BONE MARROW MYELODYSPLASIA IN LESCH-NYHAN SYNDROME	Maciej Machaczka	Received

1144-PS	CORD BLOOD DERIVED GAMMA-DELTA T CELLS CAN BE EXPONENTIALLY EXPANDED IN VITRO TO INDUCE POTENT CYTOTOXICITY AGAINST HUMAN ACUTE MYELOID LEUKEMIA CELLS	Alice Cheung	Received

1146-PS	INTERLEUKIN-15-CULTURED DENDRITIC CELLS ENHANCE ANTI-TUMOR GAMMA DELTA T CELL FUNCTIONS THROUGH IL-15 SECRETION	Heleen Van Acker	Received

1152-PS	MTL-CEBPA, A SMALL ACTIVATING RNA FOR INTRAVENOUS ADMINISTRATION TO ENHANCE C/EBP? EXPRESSION IN PATIENTS WITH LIVER CANCER SHOWS POTENTIAL USE IN NEUTROPENIA	Choon Ping Tan	Received

1153-PS	SIGNIFICANT ARI-0001 (A3B1:CD8:4-1BB:CD3Z CAR19) CELL EXPANSION IN A PATIENT WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PRE-LYMPHOAPHERESIS IBRUTINIB ADMINISTRATION.	Valentín Ortiz-Maldonado	Received

1155-PS	THE COMBINATION OF CD19/BCMA-DIRECTED CART CELLS INDUCED THERAPEUTIC RESPONSE AND REVERSIBLE COMPARTMENTAL CYTOKINE RELEASE SYNDROME CONFINED TO CEREBRAL REGION IN A PATIENT WITH CNS MULTIPLE MYELOMA	Caixia Li	Received

1157-PS	ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS	Ludovit Bielik	Received

1158-PS	IMMUNO-T, A MOTION COMIC EDUCATING PATIENTS AND CAREGIVERS ON HOW IMMUNOTHERAPY WORKS.	Tessa Kerre	Received

1160-PS	PROTEIN KINASE CK2 AS A NEW PLAYER IN GATA-1 REGULATION DURING ERYTHROPOIESIS	Laura Quotti Tubi	Received

1161-PS	TRANSCRIPTION FACTORS REGULATE DNA METHYLATION DYNAMICS IN HEMATOPOIETIC DEVELOPMENT	Takahiro Suzuki	Received

1162-PS	CANONICAL NOTCH SIGNALING IS DISPENSIBLE FOR ADULT STEADY-STATE AND STRESS MYELO-ERYTHROPOIESIS	Sara Duarte	Received

1163-PS	ENHANCING BONE MARROW TREPHINE BIOPSY ANALYZES: DEFINING PEDIATRIC LYMPHOID SUBPOPULATION REFEERENCE RANGES BY AUTOMATED ENUMERATION	Jacques Malherbe	Received

1165-PS	TELOMERASE TRANSCRIPTS FLOATING IN CANCER-DERIVED EXOSOMES REPROGRAM THE MICRORNA TRANSCRIPTOME PROFILE OF THE RECIPIENT CELLS	Daniela Likonen	Received

1166-PS	ALTERATIONS IN STROMAL PRECURSOR CELLS IN THE BONE MARROW OF PATIENTS WITH LEUKEMIA IN THE ONSET OF THE DISEASE AND AFTER TREATMENT	Nataliya Petinati	Received

1167-PS	LYMPHOPENIA AND RISK OF INFECTIONS AND INFECTION-RELATED DEATH IN DENMARK, 2003-2013: A PROSPECTIVE COHORT STUDY OF 98,344 INDIVIDUALS FROM THE GENERAL POPULATION	Marie Warny	Received

1168-PS	HEMATOPOIETIC EFFECTS OF A COMPOUND: SXN AGAINST MYELOSUPPRESSION	Lu Ding	Received

1170-PS	IMPACT OF SPLENECTOMY ON CD34+ BLOOD COUNT	Valery Savchenko	Received

1173-PS	NIVOLUMAB TREATMENT DISCONTINUATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY EXPERIENCE	Liudmila Fedorova	Received

1174-PS	BENDAMUSTINE IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER FAILURE OR SUBOPTIMAL RESPONSES TO NIVOLUMAB THERAPY.	Kirill Lepik	Received

1175-PS	NIVOLUMAB RESTORES SENSITIVITY TO CHEMOTHERAPY IN CHEMOREFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS	Eva Hortas	Received

1178-PS	RELEVANCE OF PRE AND POST TRANSPLANT PET AND HASENCLEVER INDEX IN PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT FOR HODGKIN LYMPHOMA	Siddharth Turkar	Received

1179-PS	A REAL WORLD STUDY OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF HODGKIN LYMPHOMA IN MALAYSIA: A SINGLE CENTER EXPERIENCE IN A RESOURCE LIMITED SETTING	Tze Shin Leong	Received

1180-PS	PROGNOSTIC VALUE OF FDG-PET QUANTITATIVE ASSESSMENT OF TUMOR REDUCTION BY ?SUVMAX, ?TMTV AND ?TLG IN HODGKIN LYMPHOMA PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIEIC STEM CELL TRANSPLANTATION	Pilar Perlaza	Received

1184-PS	THE IMPACT OF CXCR4 MUTATION SUBTYPES IN THE RESPONSE AND PROGRESSION-FREE SURVIVAL OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB	Jorge Castillo	Received

1187-PS	CHARACTERIZAITON OF MALT LYMPHOMA WITH T(11;18): LONG-TERM FOLLOW-UP	Kosuke Toyoda	Received

1188-PS	CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): DESCRIPTION OF MAIN DISEASE FEATURES, CLINICAL COURSE AND OUTCOME IN A SERIES OF 98 CASES.	Christina Kalpadakis	Received

1190-PS	IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME	Jorge Castillo	Received

1192-PS	CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA (OAL): LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.	Ritsuko Nakai	Received

1193-PS	CD5-NEGATIVE MANTLE CELL LYMPHOMA: A DIAGNOSTIC CHALLENGE IN LEUKEMIC NON-NODAL CASES EXCLUSIVELY DIAGNOSED IN PERIPHERAL BLOOD	Sara Montesdeoca	Received

1194-PS	MARGINAL-ZONE LYMPHOMA WITH AND WITHOUT ASSOCIATION OF HEPATITIS C VIRUS INFECTION: CLINICAL CORRELATION AND TREATMENT RESULTS	Gaiane Tumian	Received

1195-PS	STUDY OF THE DISSEMINATION PATTERNS AND CLONAL RELATIONSHIP IN DIFFERENT SITES IN MULTI-SITED MALT LYMPHOMAS. A SINGLE CENTRE ANALYSIS.	Maria Condom	Received

1199-PS	INTESTINAL COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE PATHOGENS IN HEMATOLOGICAL PATIENTS: REAPPRAISAL OF SELECTIVE ORAL DECONTAMINATION	Igor Stoma	Received

1200-PS	PREVALENCE AND RISK FACTORS OF RESISTANT GRAM-NEGATIVE BACILLI COLONIZATION AND INFECTION IN HOSPITALIZED HAEMATOLOGICAL PATIENTS	Ana Pilar Gonzalez-Rodriguez	Received

1201-PS	PEDIATRIC INTENSIVE CARE ADMISSIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA	Melpomeni Rompola	Received

1203-PS	COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA (MDRB) IS ASSOCIATED WITH COMPLICATIONS AND POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)	Alessandro Busca	Received

1206-PS	EMERGING MICROBIAL RESISTANCE IN FEBRILE NEUTROPENIA- IS IT HIGH TIME TO EVALUATE QUALITY CONTROL MEASURES?	Nida Anwar	Received

1207-PS	THERAPEUTIC ADMINISTRATION OF IGM-ENRICHED IMMUNOGLOBULINS IMPROVES SURVIVAL IN HEMATOLOGICAL CANCER PATIENTS WITH SEVERE NEUTROPENIC SEPSIS	Alessandra Forcina	Received

1208-PS	TETANUS, DIPHTHERIA AND POLIO IMMUNITY AFTER CHEMOTHERAPY AND RITUXIMAB IN PATIENTS WITH LEUKEMIA AND LYMPHOMA	Sigrun Einarsdottir	Received

1209-PS	THE DIAGNOSTIC UTILITY AND SENSITIVITY OF THE XPERT® MTB/RIF ASSAY IN DIAGNOSING MYCOBACTERIUM TUBERCULOSIS IN BONE MARROW ASPIRATE SPECIMENS	Nadhiya Subramony	Received

1210-PS	CLINICAL AND MICROBIOLOGICAL PROFILE OF BLOODSTREAM INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND FEBRILE NEUTROPENIA	Gustavo Mendez	Received

1212-PS	VACCINATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS – GUIDELINE OF THE INFECTIOUS DISEASES WORKING PARTY (AGIHO) OF THE GERMAN SOCIETY FOR HEMATOLOGY AND MEDICAL ONCOLOGY (DGHO)	Sibylle Mellinghoff	Received

1213-PS	CHARACTERISTICS OF HEMATOLOGICAL PATIENTS WITH BLOOD CULTURES PROVEN SEPSIS – EXPERIENCE OF ONE CENTER	Karla Misura Jakobac	Received

1214-PS	CHARACTERISTICS AND OUTCOME OF POLYMICROBIAL BLOODSTREAM INFECTIONS (P-BSI) IN PATIENTS WITH HEMATOLOGICAL CANCER.	Maria Elena Zannier	Received

1215-PS	IS ANTIMICROBIAL PROPHYLAXIS NECESSARY FOR LYMPHOMA PATIENTS? A SINGLE CENTRE, REAL-LIFE EXPERIENCE	Abdulkerim Yildiz	Received

1216-PS	CASTLEMAN DISEASE WITH THE EXPERIENCE OVER 17 YEARS	Guray Saydam	Received

1217-PS	EFFECTIVENESS OF DIFFERENT IRON ORAL FORMULATION IN IRON DEFICIENCY ANEMIA DUE TO GASTROINTESTINAL BLEEDING: MULTICENTRIC RANDOMIZED STUDY.	Giulio Giordano	Received

1218-PS	RENAL FUNCTION IN TRANSFUSION-DEPENDENT ?-THALASSEMIA PATIENTS: A DECADE OF FOLLOW-UP AND COMPARISON BETWEEN CHELATION REGIMES	Osama Tanous	Received

1219-PS	GENETIC STUDIES REVEAL NEW MUTATIONS IN THE CP GENE IN ACERULOPLASMINEMIA PATIENTS	Giacomo Marchi	Received

1220-PS	DIAGNOSIS OF HEREDITARY HAEMATOLOGICAL DISEASES USING NEXT GENERATION SEQUENCING PANELS	Mayka Sanchez	Received

1223-PS	IRON DEFICIENCY ANAEMIA – ZINC PROTOPORPHYRIN, A SIMPLE, FAST, INEXPENSIVE DIAGNOSTIC METHOD	João Silva Gomes	Received

1224-PS	STUDY OF A MEDICO-ECONOMIC ADVANTAGE IN USING NEW PARAMETERS OF CBC-DIFF-RETIC IN THE EARLY DETECTION OF IRON DEFICIENCY FOR DIALYSIS PATIENTS**	Elena Sukhacheva	Received

1225-PS	ACERULOPLASMINAEMIA - THE EXTREMELY RARE ALSO EXISTS	João Silva Gomes	Received

1226-PS	IT TAKES A LOT OF IRON TO AVOID TRANSFUSION	Magda Al-Obaidi	Received

1227-PS	PANCREATIC IRON LOADING IN EMOGLOBINOPATHIES.	Antonella Meloni	Received

1228-PS	CHR AND %HYPO: BETTER METHODS FOR ASSESSING FUNCTIONAL IRON DEFICIENCY IN CHRONIC KIDNEY DISEASE?	Laura Smith	Received

1231-PS	EXPLORING THE LONG NON-CODING RNA TRANSCRIPTOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA	Mattias Hofmans	Received

1235-PS	MDS WITH P53 DYSFUNCTION: A NEW PROGNOSTIC AND PREDICTIVE CATEGORY. A STUDY FROM THE ITALIAN MDS CLINICAL NETWORK	Marianna Rossi	Received

1237-PS	ALTERED CARBONYLATION PATTERN IN MYELODISPLASTIC SYNDROMES	Alba Rodríguez García	Received

1238-PS	EXPRESSION LEVEL OF SPECIFIC MIRNAS BEFORE AZACITIDINE THERAPY INITIATION MAY PREDICT FUTURE EFFICACY OF THE TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA	Michaela Dostalova Merkerova	Received

1239-PS	MULTICENTRIC VALIDATION OF THE "MONOCYTE ASSAY" FOR CHRONIC MYELOMONOCYTIC LEUKEMIA DIAGNOSIS BY FLOW CYTOMETRY	Orianne Wagner-Ballon	Received

1240-PS	CHARACTERIZATION AND DIFFERENTIAL EFFECTS OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Manja Wobus	Received

1241-PS	MYELODISPLASTIC SYNDROMES: MECHANISMS INVOLVED IN THE TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML)	Francisca Hernández Mohedo	Received

1243-PS	AUTOPHAGY IN MYELODYSPLASTIC SYNDROMES: THE ROLE OF HIF-1A/REDD1 MOLECULAR PATHWAY	Ioanna Stergiou	Received

1245-PS	SINGLE AGENT TALACOTUZUMAB IN ELDERLY HIGH-RISK MDS OR AML PATIENTS FAILING HYPOMETHYLATING AGENTS – RESULTS OF THE SAMBA STUDY BY THE EMSCO NETWORK	Uwe Platzbecker	Received

1246-PS	HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Liat Shargian-Alon	Received

1248-PS	A SYSTEMATIC REVIEW PROVIDES LIMITED CLINICAL EVIDENCE FOR ADDITIONAL EFFICACY OF G-CSF + ESA COMPARED TO FULL-DOSE ESA ALONE IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW-RISK MDS	Lucas Affentranger	Received

1249-PS	LOW RISK MDS WITHOUT RING SIDEROBLASTS. CLINICAL AND BIOLOGICAL CHARACTERIZATION FROM THE SPANISH GROUP OF MDS.	Félix López Cadenas	Received

1250-PS	SEROTONIN RECEPTOR TYPE 1B CONSTITUTES A THERAPEUTIC TARGET FOR MDS AND CMML.	Antonia Banus Mulet	Received

1251-PS	INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS	Paolo Strati	Received

1252-PS	FETAL HEMOGLOBIN INDUCTION DURING DECITABINE TREATMENT OF ELDERLY MDS/AML PATIENTS: A POTENTIAL DYNAMIC BIOMARKER FOR OUTCOME	Julia Stomper	Received

1253-PS	CLINICAL IMPACT ON THE THERAPEUTIC STRATEGY ADAPTED TO THE MUTATIONAL PROFILE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL(5Q)	Carolina Alarcón-Payer	Received

1254-PS	CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH 5-AZACYTIDINE. RESULTS FROM THE HELLENIC 5-AZACYTIDINE REGISTRY.	Panagiotis Diamantopoulos	Received

1256-PS	PREDICTIVE FACTORS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN HIGH-RISK OLDER PATIENTS WITH MDS AND CMML UNDER HYPOMETHILATING AGENTS. LATIN-AMERICAN MDS GROUP - GLAM	Marcelo Iastrebner	Received

1257-PS	IRON SUPPORT ENHANCES ERYTHROPOIETIN EFFECTIVENESS IN REFRACTORY ANEMIA WITH HIGH RETICULOCYTE COUNT, TRANSFERRIN SATURATION BELOW 30% AND HIGH LEVEL OF ERYPTOSIS.	Giulio Giordano	Received

1259-PS	SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT	Carolina Lazzarino	Received

1260-PS	TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA	Cesarina Giallongo	Received

1261-PS	WHOLE EXOME SEQUENCING OF SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS	Isabel Cuenca	Received

1263-PS	A HIGH LEVEL OF GENOMIC COMPLEXITY CORRELATES WITH ADVANCED PLASMA CELL DIFFERENTIATION STAGES IN NEWLY DIAGNOSED MM PATIENTS	Marina Martello	Received

1265-PS	SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA	Muntasir Mamun Majumder	Received

1266-PS	ADAR1-MEDIATED-NEIL1 EDITING IS OF BIOLOGICAL SIGNIFICANCE IN MULTIPLE MYELOMA	Phaik Ju Teoh	Received

1267-PS	DETECTION OF MYD88 AND CXCR4 MUTATIONS IN CELL-FREE DNA OF PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES	Tina Bagratuni	Received

1268-PS	NEXT-GENERATION SEQUENCING ALTERNATIVES FOR THE DETECTION AND QUANTIFICATION OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS	Alejandro Medina	Received

1270-PS	BONE MARROW MACROPHAGES IN PATIENTS WITH MULTIPLE MYELOMA IN COMPLETE REMISSION RETAIN PRO-TUMOR M2 PHENOTYPE	Ester Lozano	Received

1271-PS	PTC-028 DEMONSTRATES POTENT PRE-CLINICAL ACTIVITY AND PROVIDES A NOVEL OPPORTUNITY TO MODULATE BMI1 IN MULTIPLE MYELOMA	Heinz Ludwig	Received

1272-PS	ARGININE DEPRIVATION SUSTAINS PLASMA CELL FITNESS AND BIOENERGETICS IN MULTIPLE MYELOMA	Alessandra Romano	Received

1273-PS	DEMETHYLATION SENSITISES T(4;14) MULTIPLE MYELOMA TO RAS-MAPK PATHWAY INHIBITION	Jay Hocking	Received

1274-PS	CD96 (TACTILE) NEGATIVELY REGULATES THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA	Michael O´Dwyer	Received

1275-PS	GLUTAMINE-DEPENDENCE TARGETING BY ASPARAGINASE SIGNIFICANTLY INCREASES ANTI-MM ACTIVITY OF PROTEASOME INHIBITION	Paola Minetto	Received

1276-PS	MITOCHONDRIAL ACTIVITY PLAYS A CRITICAL ROLE IN MULTIPLE MYELOMA RESISTANCE	Alejandra Ortiz	Received

1278-PS	CARFILZOMIB-INDUCED CARDIOTOXICITY: MOLECULAR MECHANISMS AND THE EMERGING ROLE OF METFORMIN AS A PROPHYLACTIC THERAPY	Evangelos Terpos	Received

1279-PS	JAGGED1/2 INHIBITION PROMOTES TUMOR CELLS RESPONSE TO BORTEZOMIB IN A ZEBRAFISH MODEL OF MULTIPLE MYELOMA	Michela Colombo	Received

1281-PS	MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS.	Vittorio Emanuele Muccio	Received

1282-PS	MULTIPLE MYELOMA PATHOGENESIS: THE ROLE OF JUNB IN BONE MARROW ANGIOGENESIS	Stefano Malvestiti	Received

1284-PS	WNT/?-CATENIN AND HEDGEHOG INHIBITORS AS THERAPEUTIC APPROACHES IN B-CELL NEOPLASMS	Ana Bela Sarmento Ribeiro	Received

1285-PS	MULTIPLE MYELOMA INDUCES CHANGES IN BONE MARROW ADIPOCYTES IN VITRO AND IN VIVO	Michaela Reagan	Received

1286-PS	PROTEIN KINASE CK1 ALPHA MODULATES PROSURVIVAL AUTOPHAGY IN MULTIPLE MYELOMA	Marilena Carrino	Received

1287-PS	SERUM LIPID METABOLOMICS AS AN USEFUL BIOMARKER PREDICTING FOR THE EFFICACY OF BORTEZOMIB TREATMENT AND PERIPHERAL NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA	Masaki Ri	Received

1288-PS	CIRCULATING SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS REFLECTS RENAL FUNCTION IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TREATED WITH BORTEZOMIB-BASED THERAPY	Evangelos Terpos	Received

1289-PS	PAN-ANTI-FGF-BASED THERAPY AS A NOVEL THERAPEUTIC INTERVENTION IN WALDENSTROM´S MACROGLOBULINEMIA	Antonio Sacco	Received

1290-PS	EVALUATION OF THE ACTIVITY OF IMIDS IN MM PROLIFERATING CELLS	Joan Ballesteros	Received

1293-PS	DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY)	Sara Bringhen	Received

1295-PS	SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS	Rowan Kuiper	Received

1296-PS	CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)	Chandramouli Nagarajan	Received

1299-PS	LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.	Francesca Gay	Received

1301-PS	TREATMENT AND SURVIVAL OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY AMONG 179 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 1989 TO 2015	Mirian Brink	Received

1303-PS	REAL WORLD CLINICAL IMPLICATIONS OF THE LIMITATIONS ASSOCIATED WITH THE REVISED INTERNATIONAL STAGING SYSTEM: UNSELECTED PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NOVEL AGENTS IN AGEING SOCIETY	Yoshiaki Abe	Received

1304-PS	EVALUATION OF MINIMAL RESIDUAL DISEASE USING NEXT GENERATION FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS	Ioannis Kostopoulos	Received

1305-PS	EARLY LIGHT CHAIN KINETICS AND DEPTH/DURATION OF HEMATOLOGIC RESPONSES TO DARATUMUMAB IN PREVIOUSLY TREATED LIGHT CHAIN AMYLOIDOSIS	Gregory Kaufman	Received

1306-PS	EFFICACY AND TOLERABILITY OF DARATUMUMAB AFTER ALLOGENEIC TRANSPLANTATION FOR HEAVILY TREATED MULTIPLE MYELOMA.	Ana Pilar Gonzalez-Rodriguez	Received

1308-PS	COMPLETE RESPONSE AND INDUCTION TREATMENT DOES NOT AFFECT SURVIVAL IN MYELOMA PATIENTS RELAPSING WITHIN 18 MONTHS FOLLOWING UP-FRONT HDM-ASCT. A POPULATION-BASED STUDY FROM 1994 TO 2015	Annette Vangsted	Received

1311-PS	SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA	Marcella Tschautscher	Received

1314-PS	BONE MARROW PLASMA CELL INFILTRATION IN LIGHT-CHAIN AMYLOIDOSIS: IMPACT ON ORGAN INVOLVEMENT AND OUTCOME	Luis Gerardo Rodríguez-Lobato	Received

1315-PS	TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE	Richa Manwani	Received

1316-PS	TANDEM TRANSPLANTATION OVERCOMES POOR PROGNOSIS IN NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA WITH HIGH-RISK CYTOGENETICS: A RETROSPECTIVE STUDY BY THE CMWP-EBMT	Nico Gagelmann	Received

1319-PS	DISEASE ASSESSMENT BY PET-CT PLUS FLOW CYTOMETRY IN MULTIPLE MYELOMA IDENTIFIES PATIENTS WITH DIFFERENT SURVIVAL OUTCOMES	Rafael Alonso Fernández	Received

1321-PS	IXAZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE FOR INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Heinz Ludwig	Received

1323-PS	THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS	Tobias Wirenfeldt Klausen	Received

1324-PS	COMPARISON OF LYMPHOTRACK® MISEQ® ASSAYS AND FLOW CYTOMETRY FOR CLONALITY AND MINIMUM RESIDUAL DISEASE ASSESSMENT IN MULTIPLE MYELOMA	Ying Huang	Received

1325-PS	QUALITY OF HEMATOLOGIC RESPONSE BUT NOT DEPTH OF NT-PROBNP RESPONSE IMPROVES SURVIVAL OF PATIENTS WITH AL AMYLOIDOSIS WHO ACHIEVE CARDIAC RESPONSE	Paolo Milani	Received

1326-PS	SUSTAINED MRD NEGATIVITY AT 12 MONTHS POST-ASCT PREDICTS OUTCOMES FOR MYELOMA PATIENTS: A REAL WORLD STUDY.	Michael Austin	Received

1327-PS	MULTIPLE MYELOMA IN PATIENTS UNDER 40 YEARS OLD: A RETROSPECTIVE ANALYSIS FROM THE INTERGOUPE FRANCOPHONE DU MYELOME (IFM).	Alexis Caulier	Received

1328-PS	AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM).	Michaela Kotrova	Received

1330-PS	A REAL WORLD RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: CLINICAL FEATURES AND OUTCOME	Meral Beksac	Received

1332-PS	COMPARABLE OUTCOMES USING PROPYLENE GLYCOL-FREE MELPHALAN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA	Kevin Miller	Received

1335-PS	ASYMPTOMATIC HEART INVOLVEMENT IN AL AMYLOIDOSIS	Marco Basset	Received

1336-PS	RANDOMIZED CLINICAL TRIAL (RCT) REPRESENTATIVENESS & OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REAL WORLD (RW) PATIENTS: COMPARISON OF ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTS	Ajai Chari	Received

1338-PS	A PHASE II STUDY OF SELINEXOR(KPT-330) COMBINED WITH BORTEZOMIB AND DEXAMETHASONE (SVD) FOR INDUCTION AND CONSOLIDATION FOR PATIENTS WITH PROGRESSIVE OR REFRACTORY MULTIPLE MYELOMA: THE SELVEDEX TRIAL	Annemiek Broijl	Received

1339-PS	LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Qaiser Bashir	Received

1340-PS	THE SCREENING OF PROTEINS SIGNATURES WITH SIGNALING PATHWAY IN POLYCYTHEMIA VERA AND INHIBITION OF PIM ENHANCES JAK2 INHIBITOR SENSITIVITY	Wuhan Hui	Received

1341-PS	IMPACT OF MOLECULAR ANALYSIS ON PROGNOSTIC SCORES IN ESSENTIAL THROMBOCYTHEMIA: A SINGLE CENTER PROSPECTIVE COHORT EXPERIENCE	Damien Luque Paz	Received

1342-PS	THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN MYELOPROLIFERATIVE NEOPLASMS	Kira Behrens	Received

1344-PS	PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS	Jaqueline Cristina Fernandes	Received

1346-PS	POLO-LIKE KINASE-1, AURORA KINASE A AND WEE1: NEW THERAPEUTIC TARGETS IN SYSTEMIC MASTOCYTOSIS	Manuela Mancini	Received

1347-PS	NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS	Alfio Bonanno	Received

1348-PS	POSSIBLE SOMATIC MOSAICISM OF THE JAK2 GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS	Naoki Mori	Received

1349-PS	MULTICENTER SURVEY ON MANAGEMENT AND OUTCOME OF A RARE HEMATOLOGIC DISEASE: ADULT ONSET HISTIOCYTOSES.	Davide Lazzarotto	Received

1351-PS	DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA LOMBARDA (IRON-M STUDY)	Elena Maria Elli	Received

1352-PS	MYELOID AND LYMPHOID NEOPLASMS ASSOCIATED WITH PDGFRA AND PDGFRB REARRANGEMENTS: CLINICAL CORRELATES AND SURVIVAL OUTCOMES.	Abhishek Mangaonkar	Received

1353-PS	ASSESSING SERUM ALBUMIN CONCENTRATION, LYMPHOCYTE COUNT AND PROGNOSTIC NUTRITIONAL INDEX MIGHT IMPROVE PROGNOSTICATION IN PATIENTS WITH MYELOFIBROSIS	Marko Lucijanic	Received

1354-PS	LONG-TERM OUTCOME OF PATIENTS WITHS PLANCHNIC VEIN THROMBOSIS AND MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER EXPERIENCE	Danijela Lekovic	Received

1355-PS	GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS FROM THE MYSEC PROJECT	Daniela Barraco	Received

1356-PS	TARGETED TREATMENT WITH DIVERSE TYROSINE KINASE INHIBITORS IN PATIENTS WITH PCM1-JAK2, BCR-JAK2 AND ETV6-ABL1 POSITIVE EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS	Georgia Metzgeroth	Received

1359-PS	LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA	Yoshinori Hashimoto	Received

1360-PS	SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT).	Sarah Wharin	Received

1361-PS	FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES	Margherita Maffioli	Received

1362-PS	THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS OF POLYCYTHAEMIA VERA IN A SINGLE CENTER POPULATION	Natalia Curto-Garcia	Received

1363-PS	MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY	Caroline Mcnamara	Received

1364-PS	JAK2 ALLELIC RATIO PREDICT HIGHER TROMBOTIC RISK IN MYELOFIBROSIS PATIENTS. A SINGLE CENTER EXPERIENCE ON 143 PATIENTS.	Mirko Farina	Received

1366-PS	THE "MYMPN" PATIENT REGISTRY: VALIDATION OF A PROSPECTIVE MYELOPROLIFERATIVE NEOPLASM PATIENT REGISTRY	Robyn Scherber	Received

1367-PS	THE RELATIONSHIP OF BODY MASS INDEX TO SYMPTOM BURDEN IN THE MYELOPROLIFERATIVE NEOPLASMS	Robyn Scherber	Received

1368-PS	MANAGEMENT AND OUTCOME OF PATIENTS DIAGNOSED WITH POLYCYTHEMIA VERA IN YOUNG AGE	Giulia Bogoni	Received

1370-PS	TREATMENT STRATEGIES FOR POLYCYTHEMIA VERA: OBSERVATIONS IN A DUTCH ´REAL-WORLD´ COHORT STUDY	Peter Westerweel	Received

1371-PS	PREGNANCY OUTCOMES IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RETROSPECTIVE ANALYSIS	Bozena Sokolowska	Received

1372-PS	SECOND MALIGNANCIES IN HIDROXYUREA AND INTERFERON TREATED PATIENTS	Telma Nascimento	Received

1373-PS	CORRELATIONS BETWEEN GENETIC AND CLINICAL CHARACTERISTICS IN PATIENTS WITH PRIMARY MYELOFIBROSIS	Liubov Polushkina	Received

1374-PS	MUTATIONAL PROFILES OF CLASSIC MYELOPROLIFERATIVE NEOPLASMS IN TAIWANESE PATIENTS: FREQUENCY AND CLINICAL CORRELATION	Huan-Chau Lin	Received

1376-PS	CYCLIN D1-MEDIATED GENE EXPRESSION DYSREGULATION IMPACTS MANTLE CELL LYMPHOMA PATHOGENESIS	Santiago Demajo	Received

1377-PS	SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE	Nathalie Faumont	Received

1378-PS	TPL2 KINASE HAS A TUMOR SUPPRESSIVE ROLE IN MYC-INDUCED LYMPHOMAGENESIS	Elias Stagakis	Received

1381-PS	THE NOVEL TUMOR SUPPRESSOR SAMHD1 IS FREQUENTLY DOWNREGULATED AND CORRELATES WITH GERMINAL CENTER PHENOTYPE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Ioanna Xagoraris	Received

1382-PS	DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2	Tomoko Shimomura Takimoto	Received

1385-PS	PD1-TIM3+ CELLS ARE THE PREDOMINANT POPULATION OF EXHAUSTED CD8+ CELLS IN FOLLICULAR LYMPHOMA WITH HIGH REACTIVATION POTENTIAL	Theodora Anagnostou	Received

1386-PS	ENZYME-FREE DIGITAL COUNTING OF ENDOGENOUS CIRCULAR RNA MOLECULES IN FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FROM PATIENTS WITH B-CELL MALIGNANCIES	Mette Dahl	Received

1387-PS	PROTEIN KINASE CK1 ?LPHA SUSTAINS MANTLE CELL LYMPHOMA SURVIVAL BY IMPINGING ON BCR-LINKED SIGNALING PATHWAYS	Sabrina Manni	Received

1388-PS	WEE1 INHIBITION ENHANCES ANTI-APOPTOTIC DEPENDENCY OF DIFFUSE LARGE B-CELL LYMPHOMA CAUSED BY CELL CYCLE ARREST AND DNA DAMAGE INDUCTION	Mathilde De Jong	Received

1389-PS	INFLUENCE OF PLASMA EBV LOAD ON PROGNOSIS OF HIV-RELATED LYMPHOMAS	Josep Muncunill	Received

1390-PS	NUCLEOLIN ENHANCED ADRIAMYCIN RESISTANCE VIA THE REGULATION OF BCL-2 EXPRESSION IN CA46 BURKITT´S LYMPHOMA CELLS	Jianda Hu	Received

1391-PS	DOMINANT CYTOTOXIC NK CELL SUBSET WITHIN CLPD-NK PATIENTS IDENTIFIES A MORE AGGRESSIVE NK CELL PROLIFERATION	Gregorio Barila´	Received

1392-PS	IDENTIFICATION OF A MIR-146B-FASL AXIS IN THE DEVELOPMENT OF NEUTROPENIA IN T-LARGE GRANULAR LYMPHOCYTES LEUKEMIA	Giulia Calabretto	Received

1394-PS	IN-SILICO DISSECTION OF DIFFUSE LARGE B CELL LYMPHOMA MICROENVIRONMENT PROVIDES A 45-GENE PANEL FOR RISK STRATIFICATION	Sabino Ciavarella	Received

1395-PS	GENOMIC CHARACTERISATION OF CIRCULATING TUMOUR DNA (CTDNA) PREFERENTIALLY IDENTIFIES EARLY CLINICALLY RELEVANT GENOMIC EVENTS AND PROVIDES INSIGHT INTO THE CLONAL ARCHITECTURE OF LYMPHOID MALIGNANCY	Piers Blombery	Received

1397-PS	MYD88 CONSTITUTIVE ACTIVATION IS DIRECTLY ABLE TO INDUCE INDOLENT LYMPHOPLASMACYTIC LYMPHOMA WITH MONOCLONAL IGM PEAK SECRETION IN 1 YEAR OLD MICE: A MODEL FOR WALDENSTROM´S MACROGLOBULINEMIA	Christelle Vincent-Fabert	Received

1398-PS	CELL OF ORIGIN AND GENOMIC PROFILE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA DETERMINED USING THE NANOSTRING LST ASSAY AND ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING	Csaba Bödör	Received

1400-PS	INSUFFICIENT RECEPTOR EDITING LEADS TO DEFECTIVE B CELL CENTRAL TOLERANCE IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)	Zi Sheng	Received

1403-PS	PREDICTIVE FACTORS FOR DEVELOPING SYSTEMIC LUPUS ERYTHEMATOSUS AFTER CHILDHOOD AUTOIMMUNE CYTOPENIA	Nathalie Aladjidi	Received

1404-PS	THE POLYMORPHISM OF CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9 GENE MAY CONTRIBUTE TO RISK OF IMMUNE THROMBOCYTOPENIA	Zi Sheng	Received

1405-PS	LABORATORY CHARACTERIZATION OF PATIENTS WITH (SUSPECTED) INHERITED PLATELET DISORDERS: RESULTS FROM THE ´THROMBOCYTOPATHY IN THE NETHERLANDS´ STUDY	Maaike Blaauwgeers	Received

1407-PS	ATRA CORRECTS IMPAIRED MACROPHAGE FUNCTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA THROUGH A20/NLRP3 SIGNALING PATHWAY	Yun He	Received

1408-PS	RH-TPO RESTORES MEGAKARYOCYTES AND BONE MARROW NICHE COMPONENTS IN THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CIRRHOSIS ASSOCIATED WITH HEPATITIS B	Wan-Yi Zhai	Received

1409-PS	A HIGH-THROUGHPUT SCREENING ASSAY TO EVALUATE CHEMOTHERAPY-INDUCED MYELOSUPPRESSION USING HEALTHY PERIPHERAL BLOOD AND BONE MARROW	Komal Kumar Javarappa	Received

1413-PS	INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM IN EGYPTIAN CHILDREN AND ADOLESCENTS WITH IMMUNE THROMBOCYTOPENIA: ASSOCIATION WITH DISEASE SUSCEPTIBILITY, RESPONSE TO THERAPY AND OUTCOME	Mohammed Mostafa Al-Tawil	Received

1414-PS	CLINICAL CHARACTERISTICS AND TREATMENT COURSES FOR CYTOMEGALOVIRUS-ASSOCIATED THROMBOCYTOPENIA IN IMMUNOCOMPETENT CHILDREN AFTER NEONATAL PERIOD	Ye Jee Shim	Received

1415-PS	RAISED EXPRESSION OF APRIL IN THE PLATELET WITH IMMUNE THROMBOCYTOPENIA AND ITS CLINICAL IMPLICATIONS	yunfeng Hao	Received

1416-PS	EVALUATION OF HIT SYNDROME WITH AN AUTOMATED IMMUNOASSAY IN CORRELATION WITH THE 4T SCORE IN CARDIOVASCULAR PATIENTS	Theoni Kanellopoulou	Received

1417-PS	IMMATURE PLATELET FRACTION AS A MARKER OF THROMBOPOIESIS IN THROMBOCYTOPENIC PATIENTS	Mario Farrugia	Received

1419-PS	CHANGES IN PLATELET AGGREGATION DURING PREGNANCY AND THE IMMEDIATE POSTPARTUM PERIOD	Brwa Hussein	Received

1421-PS	THE IMPACT OF HIGH MOBILITY GROUP BOX 1 IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA	Mehmet Baysal	Received

1422-PS	WHAT ARE THE UNDERLYING CAUSES AND CLINICAL CHARACTERISTICS OF CHILDREN WITH REACTIVE THROMBOCYTOSIS AT A KOREAN TERTIARY MEDICAL CENTER?	Ye Jee Shim	Received

1424-PS	STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL PATIENTS DURING THE FIRST YEAR OF IBRUTINIB TREATMENT	Bozena Sokolowska	Received

1425-PS	VALIDATION OF THE PLASMIC SCORE FOR THROMBOTIC MICROANGIOPATIES IN A SINGLE UNVERSITY HOSPITAL	Maria Del Carmen Ballester	Received

1430-PS	IMPROVABLE LIFESTYLE FACTORS IN LYMPHOMA SURVIVORS	Carla Minoia	Received

1433-PS	THE ROLE OF MENTAL AND BEHAVIORAL DISORDERS IN LEUKEMIA PREDISPOSITION: A NATIONWIDE CASE-CONTROL STUDY	Hanna Moisander-Joyce	Received

1435-PS	QUALITY OF LIFE IN PATIENTS WITH RARE HEREDITARY HEMOLYTIC ANEMIA, THE IMPORTANCE OF SOCIAL SUPPORT	Stephanie Van Straaten	Received

1436-PS	HOW PHYSICIANS´ AND PATIENTS´ CHARACTERISTICS AFFECT THE LENGTH OF PATIENTS´ VISIT IN THE HEMATO-ONCOLOGICAL CLINIC.	Irina Amitai	Received

1439-PS	NO ASSOCIATION BETWEEN INDOOR RADON AND CHILDHOOD LEUKEMIA IN FRECCLE (FINNISH REGISTER-BASED CASE-CONTROL STUDY OF CHILDHOOD LEUKEMIA)	Atte Nikkilä	Received

1440-PS	CLARITHROMYCIN ADDED TO THE VCD REGIMEN CAUSES REDUCED HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS	Lene Kongsgaard Nielsen	Received

1441-PS	RELINF PROJECT: PROSPECTIVE EPIDEMIOLOGICAL REGISTRY OF LYMPHOID NEOPLASMS IN SPAIN, ON BEHALF OF GELTAMO GROUP	Mariana Bastos Oreiro	Received

1444-PS	HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEDIATRIC PATIENTS WITH RED CELL PYRUVATE KINASE DEFICIENCY	Paraskevi Klothaki	Received

1445-PS	QUALITY OF LIFE IS REDUCED IN PATIENTS WITH (SUSPECTED) PLATELET FUNCTION DISORDERS	Maaike Blaauwgeers	Received

1446-PS	PALLIATIVE CARE INDICATION IN ONCOHEMATOLOGIC PATIENTS: A COMPARISON TO SOLID TUMOR PATIENTS	Lucia Morais	Received

1448-PS	EFFICACY AND SAFETY OF FACILITATED SUBCUTANEOUS IGG ADMINISTRATION IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DUE TO HEMATOLOGICAL MALIGNANCIES. A SINGLE-CENTER RETROSPECTIVE ANALYSIS.	Maria Dimou	Received

1449-PS	IMPACT OF LOW GRADE ADVERSE EVENTS OF TYROSINE KINASE INHIBITORS ON THE QUALITY OF LIFE OF PATIENTS TREATED FOR CHRONIC MYELOID LEUKEMIA	Benlazar Sidi Mohamed El Amine	Received

1450-PS	HEME-INDUCIBLE LIPID OXIDATION PATTERN SUPPORTS MONITORING OF CELL-FREE HEMOGLOBIN ACTIVITY IN PATIENTS WITH SICKLE CELL DISEASE.	Jeremy Deuel	Received

1452-PS	THE OXYGENSCAN: CONTINUOUS MEASUREMENT AND QUANTIFICATION OF SICKLING DURING DE- AND REOXYGENATION TO MONITOR DISEASE SEVERITY AND TREATMENT EFFECT IN SICKLE CELL DISEASE.	Eva Hortas	Received

1454-PS	EARLY RECOGNITION OF THE SICKLING PROCESS OF ERYTHROCYTES BY LABEL-FREE LIGHT MICROSCOPIC IMAGING IN PATIENTS WITH SICKLE CELL DISEASE	Irene Metze	Received

1456-PS	IMPROVEMENT OF THE MULTIDISCIPLINARY MANAGEMENT OF SICKLE CELL DISEASE PATIENTS: IMPLEMENTATION OF A SICKLE CELL DISEASE PATIENT´S CLINICAL DATABASE: BELGIAN REGISTER OF SICKLE CELL DISEASE PATIENTS	Beatrice Gulbis	Received

1458-PS	CORRELATION BETWEEN HEMOLYSIS AND HYPERCOAGULABILITY MARKERS AND EFFECTS OF HYDROXYUREA THERAPY IN SICKLE CELL PATIENTS	Wouitchékpo V Tonassé	Received

1459-PS	INFLUENCE OF BCL11A POLYMORPHYSMS ON FETAL HEMOGLOBIN LEVELS AND HAEMOLYSIS MARKERS IN SICKLE CELL ANEMIA PEDIATRIC PATIENTS NOT RECEIVING HYDROXYUREA	Dalila Luciola Zanette	Received

1462-PS	OUTCOME OF PHILADELPHIA CHROMOSOME-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS RECEIVING TYROSINE KINASE INHIBITOR MAINTENANCE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Tuija Tapaninen	Received

1463-PS	PD-1 OVEREXPRESSION ON BONE MARROW RESIDENT CD8+ MEMORY T-CELL SUBSETS COULD BE A PREDICTABLE MARKER FOR LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.	Mikhail Drokov	Received

1464-PS	OUTCOME OF SECOND SOLID CANCER AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COHORT STUDY ON 4065 PATIENTS ON BEHALF OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY OF THE EBMT	Andre Tichelli	Received

1465-PS	SIMILAR OUTCOMES OF REDUCED INTENSITY HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO MATCHED UNRELATED DONOR TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA. A JOINT ANALYSIS FROM CIBMTR-LC & EBMT-LWP.	Katarina Gluic	Received

1466-PS	TARGETING EXPANDED GUT HOMING EFFECTOR T CELL LINEAGES IN ACUTE INTESTINAL GRAFT VERSUS HOST DISEASE: IMPLICATIONS FOR VEDOLIZUMAB	Polychronis Pavlidis	Received

1467-PS	ELTROMBOPAG TO IMPROVE PLATELET RECOVERY IN HAPLOIDENTICAL STEM CELL TRANSPLANTS (HAPLO-SCT): RESULTS OF A PHASE II TRIALPLUS A COMPARISON TO CONTROL PATIENTS	Uday Popat	Received

1468-PS	ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOMES THE NEGATIVE PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN TRANSPLANT ELIGIBLE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA.	Prateek Pophali	Received

1469-PS	ASSOCIATION OF SOCIO-ECONOMIC FACTORS WITH SURVIVAL OF PATIENTS WHO EXPERIENCE SEVERE CLASSIC ACUTE GVHD AFTER ALLO-HSCT. A RETROSPECTIVE STUDY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY, EBMT	Andrzej Frankiewicz	Received

1470-PS	COMPARISON OF REDUCED-INTENSITY CONDITIONING REGIMENS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA > 45 YEARS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY BY THE ALWP/EBMT	Zinaida Peric	Received

1471-PS	A PHASE I/II TRIAL OF INTRAVENOUS AZACITIDINE FOR ACUTE GVHD PROPHYLAXIS IN PATIENTS UNDERGOING MATCHED UNRELATED STEM CELL TRANSPLANTATION: INTERIM PHASE II RESULTS	Mark Schroeder	Received

1474-PS	PLASMA PRESEPSIN LEVEL IS A PREDICTIVE MARKER OF SEVERE ACUTE GVHD AFTER ALLO-HSCT: USEFULNESS AS A BIOMARKER OF ALLO-HSCT RELATED COMPLICATION	Tatsuo Oyake	Received

1476-PS	EFFECTS OF POST-AUTO-HSCT MRI BONE MARROW LESIONS ON PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MM	Maxim Solovev	Received

1477-PS	COMBINED EVALUATION OF DISEASE RISK INDEX AND ABCG2 EXPRESSION IDENTIFY AML PATIENTS AT A VERY HIGH RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Daniela Damiani	Received

1479-PS	A NEW ULTRASONOGRAPHY-BASED SCORING SYSTEM IS EFFECTIVE DIAGNOSTIC TOOL FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	Mutsumi Nishida	Received

1481-PS	CHANGES IN THE NUMBER OF BONE MARROW LESIONS AND TUMOUR MASS ON MRI IN PATIENTS WITH MM FOLLOWING AUTO-HSCT	Maxim Solovev	Received

1483-PS	ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FOR NON-HODGKIN´S LYMPHOMA IN SWITZERLAND. 30 YEARS OF EXPERIENCE 1985-2017.	Ekaterina Chigrinova	Received

1485-PS	PROGNOSTICATION OF CHRONIC GRAFT VERSUS HOST DISEASE: THE IMPACT OF IMMUNE RECONSTITUTION.	Fabio Serpenti	Received

1486-PS	UTILIZATION AND OUTCOMES OF FERTILITY PRESERVATION TECHNIQUES IN WOMEN UNDERGOING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT	Alexandra Higgins	Received

1487-PS	LOW INCIDENCE OF SYMPTOMATIC OSTEONECROSIS AFTER ALLOGENEIC HSCT IN CHILDREN WITH HIGH-RISK OR RELAPSED ALL – RESULTS OF THE ALL-SCT 2003 TRIAL	Michaela Kuhlen	Received

1488-PS	EARLY BLOOD STREAM INFECTION AFTER BMT IS ASSOCIATED WITH CYTOKINE DYSREGULATION AND POOR OVERALL SURVIVAL	Kate Markey	Received

1489-PS	REGRESSION TREE BASED MODEL FOR PREDICTING NON-RELAPSE MORTALITY IN AML PATIENTS ALLO-TRANSPLANTED IN FIRST COMPLETE REMISSION	Anish Nair	Received

1492-PS	SUBPOPULATIONS OF MONOCYTES AND B REGULATORY CELLS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE	Antonija Babic	Received

1493-PS	LIFESTYLE BEHAVIOR AMONG LYMPHOMA SURVIVORS AFTER HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	Hanne Skjerven Bersvendsen	Received

1494-PS	CTLA-4 GENE POLIMORPHISM INFLUENCE THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION	Petra Kovy	Received

1497-PS	INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS ON HAPLOIDENTICAL TRANSPLANTATION	María Perera Alvarez	Received

1500-PS	CLOFARABINE- BASED CYTOREDUCTIVE TREATMENT FOLLOWED BY MYELOABLATIVE CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH-RISK, RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES.	Diego Medina Valencia	Received

1501-PS	SELECTIVE INHIBITION OF OXIDATIVE PHOSPHORYLATION PREVENTS LETHAL GRAFT-VERSUS-HOST DISEASE WHILE MAINTAINING ANTITUMOR IMMUNITY	Zachariah Mciver	Received

1502-PS	AN UNBALANCED MONOCYTE MACROPHAGE POLARIZATION IN THE BONE MARROW MICROENVIRONMENT MAY CAUSE THE OCCURRENCE OF POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Hong-Yan Zhao	Received

1504-PS	MURINE MODELS FOR ESTABLISHING STEROID REFRACTORY GVHD	Tomomi Toubai	Received

1505-PS	LOW-DOSE INTERLEUKIN-2 RESTORING HUMAN REGULATORY T CELL FUNCTION IN VITRO AS A POTENTIAL APPLICATION FOR GVHD THERAPY AFTER TRANSPLANTATION	Tzeon-Jye Chiou	Received

1506-PS	HYPOFRACTIONATED TOTAL LYMPHOID IRRADIATION BY HELICAL TOMOTHERAPY AND HIGH DOSE CHEMOTHERAPY AS CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA	Fabio Guolo	Received

1509-PS	HEMATOLOGICAL PHENOTYPES OF DIFFERENT ALPHA-THALASSAEMIA GENOTYPES CAUSING HYPOCHROMIC MICROCYTIC ANEMIA AT NEONATAL PERIOD	Thidarat Suksangpleng	Received

1511-PS	THE STRONG LINK BETWEEN PANCREAS AND HEART IN THALASSEMIA MAJOR.	Antonella Meloni	Received

1513-PS	PRE- AND POST-TRANSFUSION COMPLEMENT ACTIVATION IN TRANSFUSION-DEPENDENT ?-THALASSAEMIA	Eleni Gavriilaki	Received

1514-PS	ASSOCIATION OF CLINICAL PHENOTYPE OF THALASSEMIA WITH COMMON FETAL HEMOGLOBIN VARIANTS IN LEBANESE PATIENTS BEARING THE CODON 29 ?ETA GENE MUTATION	Ali Taher	Received

1516-PS	ASSOCIATION OF VITAMIN D AND RETINOID X RECEPTORS EXPRESSION AND VITAMIN D BINDING PROTEIN VARIANTS WITH BONE DENSITY IN THALASSEMIA CHILDREN	Shaimaa Sahmoud	Received

1517-PS	NEW OCCURRENCES OF MACROSCOPIC MYOCARDIAL FIBROSIS IN THALASSEMIA AT LONG TERM BY MULTIPLE FOLLOW-UP	Antonella Meloni	Received

1518-PS	COMMON LINK BETWEEN BONE AND HEART HEALTH IN THALASSEMIA MAJOR.	Antonella Meloni	Received

1520-PS	CEREBRAL IRON OVERLOAD IN BETA THALASSEMIA: DOES IT REALLY MATTER?	Immacolata Tartaglione	Received

1521-PS	LEPTIN IS ASSOCIATED WITH THE DEGREE OF ANEMIA AND THE ERYTHROPOIETIN LEVELS IN ? THALASSEMIA PATIENTS	Osama Tanous	Received

1522-PS	MUTATION SPECTRUM IN HBB, HBA1 AND HBA2 GENES IN PATIENTS FROM EUROPEAN PART OF RUSSIA	Svetlana Mann	Received

1523-PS	COMPREHENSIVE SCREENING FOR COEXISTING HETEROZYGOUS ?0-THALASSEMIA IN HEMOGLOBIN E TRAIT	Piroonrut Wongprachar	Received

1524-PS	INVOLVEMENT OF LEUCOCYTE DERIVED EXTRACELLULAR VESICLES IN THE PROCOAGULANT STATE FOUND IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-RELATED CONDITION	Adeline Wannez	Received

1525-PS	ARE ALL DIRECT ORAL ANTICOAGULANTS EQUAL TO SAFETY AND EFFICACY?	Begoña Navarro Almenzar	Received

1526-PS	INCREASED PLATELET RESPONSE TO ENDOGENOUS AGONISTS, IN PRE-DIABETIC C57BL/6 MICE	Zibusiso Mkandla	Received

1527-PS	ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA AND ACUTE PANCREATITIS: VARIABLE AND RECIPROCAL PATHOPHYSIOLOGIC RELATIONSHIPS	Qian Qin	Received

1528-PS	EVALUATION OF LUPUS ANTICOAGULANT TESTING: A THREE YEAR EXPERIENCE	Sergio Felipe Pinzon	Received

1530-PS	APTT-BASED CLOT WAVEFORM ANALYSIS IN VARIOUS INFECTIONS	Cheng Kiat Lawrence Ng	Received

1534-PS	LABORATORY CRITERIA FOR THE DIAGNOSTIC RELIABILITY OF TESTS FOR DETECTION OF LUPUS ANTICOAGULANT IN PATIENTS WITH SUSPECTED ANTIPHOSPHOLIPID SYNDROME	Valeriia Krasivska	Received

1535-PS	THE COAGULATION SYSTEM FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS	Elizaveta Efremova	Received

1536-PS	PLATELET MAPPING BY THROMBOELASTOGRAPHY- ASSESSMENT OF PLATELET INHIBITION SECONDARY TO ANTIPLATELET THERAPY AFTER PCI	Dibyendu De	Received

1537-PS	IMMATURE PLATELET FRACTION: A USEFUL MARKER FOR IDENTIFYING THE CAUSE OF THROMBOCYTOPENIA AND PREDICTING PLATELET RECOVERY	Eunyup Lee	Received

1538-PS	PLATELETPHERESIS-ASSOCIATED LYMPHOPENIA IN FREQUENT PLATELET DONORS	John Gansner	Received

1539-PS	INTRACRANIAL HEMORRHAGE IN LEUKEMIA PATIENTS: PRELIMINARY RESULTS OF AN ONGOING NESTED CASE CONTROL STUDY	LL Laura Cornelissen	Received

1540-PS	QUALITY CONTROL IN CRYOPRESERVED POOLED PLATELETS: 9-YEAR EXPERIENCE IN A TRANSFUSION CENTRE.	Pablo Romero Garcia	Received

1541-PS	BACTERIAL CONTAMINANTS AND BIOFILMS EFFECT PLATELET ACTIVATION AND FUNCTION: IMPLICATIONS IN PLATELET TRANSFUSIONS	Joels Wilson-Nieuwenhuis	Received

1543-PS	MASSIVE TRANSFUSION PROTOCOLS - FRIEND OR FOE ?	Moon Ley Tung	Received

1544-PS	PLATELET-DERIVED MICROPARTICLES; THE EXPRESSION PROPERTIES AND POTENSIAL AS A SUBSTITUTE FOR PLATELETS	Shima Azadpour	Received

1545--LB-P	PSO EHA posters onsite	Eva Hortas	Received

23rd Congress of EHA

14-17 June 2018 Stockholm

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 14/06/2018 TO 14/06/2018

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.23EHA.2018



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access